PRODUCTION OF NMN AND ITS DERIVATIVES VIA MICROBIAL PROCESSES

FIELD OF THE INVENTION

The field of the invention relates to the production of nicotinamide mononucleotide (NMN) and its derivatives including nicotinamide riboside (NR) and nicotinamide adenine dinucleotide (NAD) via microbial processes.

BACKGROUND OF THE INVENTION

In recent years, nicotinamide adenine dinucleotide (NAD) has evolved from being a simple metabolic cofactor to the status of a therapeutic agent in health care applications (Katsyuba et al 2020—NAD⁺ homeostasis in health and disease. Nature Metabolism 2: 9-31). Similarly, two other compounds both closely related to NAD, namely nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), are currently recognized as nutraceuticals with potential in anti-aging and longevity applications. NMN and NR are currently produced commercially using chemical methods and there is a need for developing bioprocess technology to manufacture these compounds at commercial scales in a cost-effective way.

The bacterium Corynebacterium stationis (ATCC 6872 and variously described as Brevibacterium ammoniagenes, Corynebacterium ammoniagenes and Brevibacterium stationis) has been found to be a prolific producer of NMN and related compounds when grown under restrictive conditions. Typical restrictive conditions include starvation for manganese, addition of specific chemical inhibitors and, with specific temperature-sensitive mutants, culturing at high temperatures. Included in this stress-induced microbial production of NMN is nicotinate mononucleotide (NAMN), a compound related to NMN when the cells are grown under restrictive conditions and fed with either nicotinic acid (NA) or nicotinamide (Nam). There remains a need in the art for production methods of NMN that increase the amount of NMN produced while minimizing or eliminating the formation of side product NAMN.

SUMMARY OF THE INVENTION

The present invention addresses the need described above by providing genetic modifications to Corynebacterium glutamicum that enable the production of nicotinamide mononucleotide (NMN) rather than nicotinate mononucleotide (NAMN), as well as the production of NMN-derived molecules such as NR and NAD.

The present invention relates to engineered host cells with genetic modifications that enable the production of NMN and its derivatives NR and NAD. Also provided in this invention are methods to genetically engineer microbial host cells capable of selectively producing either NMN or NR or NAD. The feedstocks useful for the production of NMN, NR and NAD according to the present invention include nicotinamide (Nam) and nicotinic acid (NA). In a preferred embodiment of the present invention, Nam is used as the feedstock for the production of NMN, NAR or NAD.

The microbial host cells useful for the production of NMN. NR and/or NAD according to the present invention include, but are not limited to, microbial cells such as bacterial cells, fungal cells and yeast cells amenable to genetic modifications. In one aspect of the present invention, Corynebacterium glutamicum is used as the preferred microbial host cell. In a preferred aspect of this invention, Corynebacterium glutamicum cells useful for this invention are initially subjected to genetic modifications to alter its restriction modification system to make it suitable for other genetic modifications which enable to use this bacterial cell for producing NMN, NR and NAD using Nam or NA a feedstock. The present engineered host cells, including Corynebacterium glutamicum, may comprise genetic modifications for introducing a conditionally active ribonucleotide reductase to block cell division and biomass accumulation without affecting protein synthesis and normal metabolic activity, e.g., a ribonucleotide reductase coded by a NrdHIEJ operon.

In one aspect of the present invention, the genetic modifications suitable for the production of NMN, NR and/or NAD include, but are not limited to, introduction of an exogenous gene expressing an enzyme protein not originally present in the microbial host cell, increasing the relative expression of an endogenous gene coding for an enzyme protein leading to an increase in the activity of the corresponding enzyme protein, and/or decreasing or totally eliminating the expression of an endogenous gene coding for an enzyme protein causing a decrease or total elimination of the activity of the corresponding enzyme protein.

In one aspect of the present invention, where the engineered microbial host cell lacks an endogenous gene coding for an enzyme capable of converting Nam to NMN, an exogenous gene nadV coding for nicotinamide phosphoribosyl transferase enzyme is introduced into the engineered microbial host cell. In one exemplary embodiment of the present invention, the source of nadV gene coding for nicotinamide phosphoribosyl transferase enzyme includes, but is not limited to, Stenotrophomonas maltophilia, Chromobacterium violaceum, Deinococcus radiodurans, Synechocystis sp. PCC 6803, Pseudonocardia dioxanivorans CB1190, Shewanella oneidensis MR-1 and Ralstonia solanacearum GMI1000. In a most preferred aspect of the present invention, an nadV gene from any one of the foregoing microbial species is isolated and introduced into a strain of Corynebacterium glutamicum using one or more genetic engineering techniques well known in the art. In a preferred aspect, the exogenous gene nadV is codon optimized before its transfer into the engineered microbial host cell to assure optimal expression of the nicotinamide phosphoribosyl transferase enzyme in the microbial host cell. The exogenous gene within the Corynebacteriun glutamicum cell may be under an inducible promoter such as lacZ promoter and can be induced using lactose or IPTG.

In another aspect of the present invention, the NAMPT gene from Haemophilus ducreyi is introduced into the engineered microbial host cell as a source of nicotinamide phosphoribosyl transferase enzyme activity. In yet another aspect of this embodiment, in those microbial host cells already having an endogenous gene coding for nicotinamide phosphoribosyl transferase enzyme, the activity of this enzyme may be further enhanced by means of introducing an exogenous nadV gene (optionally codon-optimized and obtained from any of the sources listed in the foregoing paragraph) or an optionally codon optimized NAMPT gene from Haemophilus ducreyi.

In another aspect of the present embodiment, the microbial host cell selected for producing NMN using Nam as a feedstock and having a codon optimized exogenous gene coding nicotinamide phosphoribosyl transferase enzyme further comprises an additional genetic modification to assure the availability of phosphoribosyl pyrophosphate (PRPP also known as 5-phospho-ribose 1-diphosphate) serving as a co-substrate in the enzymatic reaction leading to the conversion of Nam to NMN. The additional genetic modification includes an introduction of an exogenous gene such as prsA, coding for the phosphoribosyl pyrophosphate synthetase or improving the performance of endogenous prsA gene either by increasing its expression or improving the performance of the phosphoribosyl pyrophosphate synthetase enzyme PrsA coded by the prsA gene. In a preferred aspect of this invention, a prsA gene coding for a feedback resistant phosphoribosyl pyrophosphate synthetase enzyme is used.

In another embodiment of this invention, as a way of conserving the PRPP serving as the co-substrate in the production of NMN from Nam, the other pathways utilizing PRPP pool within the cell are blocked. In one aspect of the present invention, the pyrE gene is mutated leading to the inactivation of the orotate phosphoribosyl transferase enzyme responsible for catalyzing the transfer of a ribosyl phosphate group from PRPP to orotate, leading to the formation of orotidine.

In another embodiment of the present invention, the microbial host cell selected for producing NMN using Nam as a feedstock and having a codon optimized exogenous gene coding for nicotinamide phosphoribosyl transferase enzyme further comprises an additional genetic modification to assure the conservation of the NMN produced within the cell using Nam as a feedstock wherein the additional genetic modification blocks other biochemical pathways that consume NMN. In one aspect of this embodiment, the ushA gene coding for an enzyme capable of the conversion of NMN to NR is deleted. In another aspect of this embodiment, the pncC gene is deleted resulting in the loss of nicotinamide-nucleotide amidohydrolase enzyme activity capable of the conversion of NMN into nicotinate mononucleotide (NAMN). In yet another aspect of this invention, the genes cgl1364, cgl1977 and cgl2835 are deleted leading to the elimination of the putative nucleosidase capable of the conversion of NMN into Nam and ribose-5 phosphate. In another aspect of this invention, the gene nadD is genetically modified so that the activity of the enzyme capable of the conversion of NMN to NAD is blocked.

In another aspect of the present embodiment, the microbial host cell selected for producing NMN using Nam as a feedstock and having a codon optimized exogenous gene coding nicotinamide phosphoribosyl transferase enzyme further comprises an additional genetic modification resulting in the knockout or impairment of a pgi gene, thereby redirecting the D-glucose-6-phosphate from glycolysis to the pentose phosphate pathway (PPP) and increasing PRPP availability. However, the deletion of pgi has been found to cause retarded growth in some microbial species in certain media. To at least partially restore normal growth, the microbial host cell may be further genetically modified to express a heterologous ZWF enzyme with a higher ability to overcome feedback inhibition relative to the native ZWF of the microbial host cell.

In non-limiting example embodiments, the transgenic ZWF enzyme may be (i) a feedback resistant mutant polypeptide comprising an amino acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or even 100% identity to the amino acid sequence as set out in SEQ ID NO: 28; (ii) a Leuconostoc mesenteroides mutant polypeptide comprising an amino acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or even 100% identity to the amino acid sequence as set out in SEQ ID NO: 30; or (iii) a polypeptide comprising an amino acid sequence having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or even 100% to the Zymomonas mobilis (zmZWF) amino acid sequence as set out in SEQ ID NO: 32.

It has also been found that, in microbial species lacking native pyridine nucleotide transhydrogenases, growth may also be rescued by overcoming NADPH accumulation. This may be achieved by further genetically modifying the host cell to include one or more soluble or membrane-bound transhydrogenases. In non-limiting examples, UdhA from E. coli is a soluble transhydrogenase that is reported to favor the reduction of NAD+ by NADPH, and PntAB from E. coli is a membrane-bound transhydrogenase that is reported to favor the reduction of NADP+ by NADH.

In one representative embodiment, the recombinant ZWFs and the transhydrogenase are paired in a cgDVS expression vector.

In various embodiments of the present invention, the microbial host cell selected for producing NMN using Nam as a feedstock and having a codon optimized exogenous gene coding for nicotinamide phosphoribosyl transferase enzyme may comprise any combination of the various genetic modifications described in the foregoing paragraphs. Accordingly, a microbial host cell according to the present invention may comprise, for example, at least one, at least two, at least three, at least four, or at least five genetic modifications as described in the foregoing paragraphs.

In a further embodiment, the present invention provides a method for producing NAD using Nam as a feedstock. In one aspect of this embodiment, the microbial host cell selected for producing NMN using Nam and having a codon optimized exogenous gene coding nicotinamide phosphoribosyl transferase enzyme further comprises an additional genetic modification in nadD gene yielding an upregulated NAD(+) synthetase enzyme responsible for the conversion of NMN to NAD. In yet another aspect of this embodiment, the gene nudC is mutated so that the enzyme responsible for the conversion of NAD back to NMN is blocked.

In yet another embodiment, the present invention provides the method for producing NR using Nam as a feedstock. In one aspect of this embodiment, the microbial host cell selected for producing NMN using Nam and having a codon optimized exogenous gene coding nicotinamide phosphoribosyl transferase enzyme further comprises a functionally active dephosphorylation enzyme coded by ushA gene. In another aspect of this invention, the ushA gene is genetically modified yielding a dephosphorylation enzyme with enhanced activity for the conversion of NMN to NR. In yet another aspect of this invention, the genes cgl1364, cgl1977 and cgl2835 are deleted leading to the elimination of the purine nucleosidase responsible for the conversion of NR into NA and ribose.

Accordingly, in one aspect, the present invention provides methods of producing NMN, wherein such method comprises: feeding Nam to a culture of a genetically modified Corynebacterium glutamicum strain, where said strain comprises at least one genetic modification selected from the group consisting of: (a) heterologous expression of an nadV gene encoding a nicotinamide phosphoribosyltransferase capable of the conversion of Nam to NMN; (b) deletion or modification of one or more genes capable of the enzymatic conversion of Nam to NA; (c) deletion or modification of one or more genes capable of the enzymatic conversion of NMN to NR; (d) modification of one or more genes capable of producing PRPP; (e) modification or deletion of PRPP-requiring biochemical pathways other than the biochemical pathway for the conversion of Nam to NMN; (f) deletion or modification of the gene capable of the enzymatic conversion of NMN to NAMN; (g) deletion or modification of the gene capable of the conversion of NMN to NAD; (h) deletion or modification of one or more genes coding for an NMN nucleosidase capable of the conversion of NMN to Nam and ribose-5-phosphate; (i) incorporation of a conditionally active ribonucleotide reductase to block cell division and biomass accumulation without affecting protein synthesis and normal metabolic activity; and (j) any combinations thereof. In various embodiments, the present genetically modified strain with said at least one modification produces an increased amount of NMN compared to a strain without any of said modifications.

Therefore, in another aspect, the present invention provides methods of producing NR, wherein such method comprises: feeding Nam to a culture of a genetically modified Corynebacterium glutamicum strain, where said strain comprises at least one genetic modification selected from the group consisting of: (a) heterologous expression of an nadV gene encoding a nicotinamide phosphoribosyltransferase capable of the conversion of Nam to NMN; (b) deletion or modification of one or more genes capable of the enzymatic conversion of Nam to NA; (c) modification of one or more genes, including ushA gene, capable of the enzymatic conversion of NMN to NR; (d) modification of one or more genes capable of producing phosphoribosyl pyrophosphate (PRPP); (e) modification or deletion of PRPP-requiring biochemical pathways other than the biochemical pathway for the conversion of Nam to NMN; (f) deletion or modification of the gene capable of the enzymatic conversion of NMN to NAMN; (g) deletion or modification of the gene capable of the conversion of NMN to NAD; (h) deletion or modification of one or more genes coding for an NMN nucleosidase capable of the conversion of NMN to Nam and ribose-5-phosphate; (i) deletion or modification of one or more genes coding for a nucleosidase capable of the conversion of NR to Nam and ribose-sugar; (j) incorporation of a conditionally active ribonucleotide reductase to block cell division and biomass accumulation without affecting protein synthesis and normal metabolic activity; and (k) any combinations thereof. In various embodiments, the present genetically modified strain with said at least one modification produces an increased amount of NR compared to a strain without any of said modifications. In some embodiments, at least one of the one or more genes coding for an NMN nucleosidase capable of converting NMN to Nam and ribose-5phosphate can be the same gene(s) as at least one of the one or more genes coding a nucleosidase capable of converting NR to Nam and ribose-sugar.

Accordingly, in yet another aspect, the present invention provides methods of producing NAD, wherein such method comprises: feeding nicotinamide to a culture of a genetically modified Corynebacterium glutamicum strain, where said strain comprises at least one genetic modification selected from the group consisting of: (a) heterologous expression of an nadV gene encoding a nicotinamide phosphoribosyltransferase capable of the conversion of Nam to NMN; (b) deletion or modification of one or more genes capable of the enzymatic conversion of Nam to NA; (c) deletion or modification of one or more genes capable of the enzymatic conversion of NMN to NR; (d) modification of one or more genes capable of producing PRPP; (e) modification or deletion of PRPP-requiring biochemical pathways other than the biochemical pathway for the conversion of Nam to NMN; (f) deletion or modification of the gene capable of the enzymatic conversion of NMN to NAMN; (g) modification of the gene capable of the conversion of NMN to NAD; (h) deletion or modification of one or more genes capable of the conversion of NAD back to NMN; (i) deletion or modification of one or more genes coding for an NMN nucleosidase capable of the conversion of NMN to Nam and ribose-5-phosphate; (j) incorporation of a conditionally active ribonucleotide reductase to block cell division and biomass accumulation without affecting protein synthesis and normal metabolic activity; and (k) any combinations thereof. In various embodiments, the present genetically modified strain with said at least one modification produces an increased amount of NAD compared to a strain without any of said modifications. In some embodiments, at least one of the one or more genes coding for an NMN nucleosidase capable of converting NMN to Nam and ribose-5-phosphate can be the same gene(s) as at least one of the one or more genes coding a nucleosidase capable of converting NR to Nam and ribose-sugar.

While the disclosure is susceptible to various modifications and alternative forms, specific embodiments thereof are shown by way of example in the drawing and will herein be described in detail. It should be understood, however, that the drawings and detailed description presented herein are not intended to limit the disclosure to the particular embodiment disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present disclosure as defined by the appended claims.

Other features and advantages of this invention will become apparent in the following detailed description of preferred embodiments of this invention, taken with reference to the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Chemical structures of desired products nicotinamide adenine dinucleotide (NAD⁺), nicotinamide mononucleotide (NMN), and nicotinamide riboside (NR). Also shown in this figure are the chemical structure of side products namely nicotinate adenine dinucleotide (NAAD), nicotinate mononucleotide (NAMN), nicotinate riboside (NAR), as well as substrates nicotinamide (Nam) and nicotinic acid (NA). The side products are eliminated by genetic modifications according to the present invention. The structures of NA, NAR, NAMN and NAAD are different from Nam, NR, NMN, and NAD respectively by the end group C(O)OH versus C(O)NH₂.

FIG. 2. Certain genetic modifications for increased production of NR, NAD and NMN according to the present teachings. Such genetic modifications may include one or more of: (a) heterologous expression of nadV gene encoding nicotinamide phosphoribosyltransferase capable of the conversion of Nam to NMN; (b) deletion or modification of one or more genes capable of the enzymatic conversion of Nam to NA; (c) deletion or modification of one or more genes capable of the enzymatic conversion of NMN to NR; (d) modification of one or more genes capable of producing PRPP; (e) modification or deletion of PRPP requiring biochemical pathways other than the biochemical pathway for the conversion of Nam to NMN; (f) deletion or modification of the gene responsible for the enzymatic conversion of NMN to NAMN; (g) deletion or modification of the gene responsible for the conversion of NMN to NAD; and (h) deletion or modification of one or more genes coding for a promiscuous NMN nucleosidase capable of the conversion of NMN to Nam and ribose-5-phosphate.

FIG. 3. Pathway for NMN production from Nam as a feedstock in an example genetically modified microbial host cell according to the present invention.

FIG. 4. Mechanism of action of purine nucleosidase known in the art and the unexpected observation of the same enzyme functioning as nicotinamide mononucleotide nucleosidase.

FIG. 5. Method used for deleting a target gene using the suicidal plasmid pDEL. As shown in this illustration, the upstream and downstream flanking regions of a target gene to be deleted were obtained using PCR and cloned into a pDEL plasmid. C. glutamicum cells were transformed with a pDEL plasmid with upstream and downstream flanking regions of the gene targeted for deletion. After transformation, the cells were plated in a kanamycin plate to select the transformants. In the second round of screening, the transformants were plated on a sucrose containing plates to select the double recombinants with the deletion of target gene.

FIG. 6. Production of NMN in two different Corynebacterium glutamicum strains constructed according to the present invention. The strain NMN4 has the genotype of Δcgl1777-8 ΔpncA ΔpncC ΔushA ΔpyrE and the strain NR5 has the genotype of Δcgl1777-8 ΔpncA ΔpncC ΔpnuC Δcgl1364 Δcgl1977 Δcgl2835.

FIG. 7. Production of NMN in four different Corynebacterium glutamicum strains constructed according to the present invention.

FIG. 8. Pathway for enhancing PRPP production from D-glucose-6-phosphate in an example genetically modified microbial host cell according to the present invention.

FIG. 9 Growth of a number of Corynabacterium glutamicum strains transformed with ZWF and transhydrogenase genes in CGXII medium.

FIG. 10 NMN production in a number of ΔPGI Corynabacterium glutamicum strains containing indicated plasmids.

DETAILED DESCRIPTION

The present invention relates to the construction of genetically modified host cells useful in the biological production of NMN, NR and NAD using Nam or NA as feedstock and the method of producing NMN, NR and NAD using those genetically modified host cells. In a preferred embodiment, Nam is used as the feedstock for the production of NMN. NR and NAD.

Genetically modified host cells useful in the present invention may be microbial cells such as bacterial cells, fungal cells and yeast cells. Bacterial cells useful in the present invention include, without limitation, Escherichia spp., Streptomyces spp., Zymomonas spp. Acetobacter spp., Citrobacter spp., Synechocystis spp., Rhizobium spp., Clostridium spp., Corynebacterium spp., Streptococcus spp., Xanthomonas spp. Lactobacillus spp. Lactococcus spp. Bacillus spp., Alcaligenes spp., Pseudononas spp., Aerononas spp., Azotobacter spp., Comamonas spp., Mycobacterium spp., Rhodococcus spp. Gluconobacter spp., Ralstonia spp. Acidithiobacillus spp., Microlunatus spp., Geobacter spp., Geobacillus spp., Arthrobacter spp., Flavobacterium spp. Serratia spp., Saccharopolyspora spp. Thermus spp., Stenotrophomonas spp. Chromobacterium spp., Sinorhizobium spp., Saccharopolyspora spp., Agrobacterium spp., Pantoea spp., and Vibrio natriegens. In a preferred embodiment, Corynebacterium glutamicum is used.

Yeast cells of the present disclosure include, without limitation, engineered Saccharomyces spp., Schizosaccharomyces, Hansenula, Candida, Kluyveromyces, Yarrowia, Candida boidinii, and Pichia. According to the current disclosure, a yeast as claimed herein are eukaryotic, single-celled microorganisms classified as members of the fungus kingdom. Yeasts are unicellular organisms which evolved from multicellular ancestors but with some species useful for the current disclosure being those that have the ability to develop multicellular characteristics by forming strings of connected budding cells known as pseudo hyphae or false hyphae.

FIG. 1 shows the chemical structures of desired products NAD, NMN and NR. Also shown in this figure are the chemical structure of side products namely NAAD, NAMN, NAR, as well as substrates Nam and NA. The side products are eliminated by genetic modifications according to the present invention. The structures of NA, NAR, NAMN and NAAD are different from Nam, NR, NMN, and NAD respectively by the end group C(O)OH versus C(O)NH₂.

FIG. 2 shows the portions of the metabolic pathway inside a C. glutamicum cell which is relevant to the present invention. The objective of the present invention is to produce NMN, NR and NAD using Nam or NA as the feedstock while eliminating related side products such as NAR, NAMN and NAAD.

In a preferred embodiment Nam is used as the feedstock. As illustrated in FIG. 2, the metabolic pathway from Nam to NMN, NR and NAD is different from the metabolic pathway from NA to NAD, NMN and NR. The pathway from NA to NAD (via NAMN and NAAD), NMN (via NAMN), and NR (via NAMN and NMN) involves significantly more enzymatic steps than the pathway from Nam to NMN, and NR and NAD (via NMN). Therefore, Nam is considered as the preferred feedstock for producing NMN, NR, and NAD.

When Nam is used as the preferred feedstock, it is advantageous to address the conversion of Nam into NA by the deamidase enzyme coded by the pncA gene. One way to eliminate the conversion of Nam into NA is to inactivate the pncA gene. The inactivation of the pncA gene can be accomplished using a number of genetic manipulation techniques. The preferred genetic manipulation of pncA gene is to delete the nucleotide sequence from the chromosomal DNA of the microbial host cell.

Using a variety of tools available for genetic manipulations, a person skilled in the art of microbial strain construction will be able to design the metabolic pathways for producing each of the desired compounds namely NMN, NR and NDA. As illustrated in FIG. 2, the production of NMN from Nam is accomplished in a single enzymatic step within the microbial host cell. Once NMN is accumulated within the microbial host cell, the other two compounds of interest namely, NDA and NR can be obtained from NMN as a derivative product through subsequent enzymatic reactions.

Tables 1-3 lists the various genes and enzymes involved in the biochemical pathways illustrated in FIG. 2. Table 4 provides the sequence information for the genes and enzymes involved in the operation of the biochemical pathways illustrated in FIG. 2.

To provide a more direct route for the production of nicotinamide NMN, NR, and NAD, a number of genetic modifications can be made to Corynebacterium glutamicum or a related organism. In some embodiments, such genetic modifications can include heterologous expression of a gene encoding nicotinamide phosphoribosyltransferase (nadV). Nicotinamide phosphoribosyltransferase is an activity not natively found in Corynebacterium. However, it is found in a number of other bacterial and eukaryotic microorganisms. Table 2 lists certain preferred sources of such gene. In some embodiments, the genetic modifications can include deletion or modification of the gene (pncA) capable of the conversion of nicotinamide to nicotinic acid resulting in the loss or decrease in enzyme activity. In some embodiments, the genetic modifications can include modification of the prsA gene capable of the production of phosphoribosyl pyrophosphate (PRPP), a key precursor to NMN, NR, and NAD, such that higher levels of PRPP are available. Such modifications can include upregulation of gene expression and/or introduction of protein variants that lead to increased levels of enzyme activity under production conditions. Modifications to the prs gene such as those described in Marinescu et al., “Beta-nicotinamide mononucleotide (NMN) production in Escherichia coli,” Sci. Rep., 8: 12278 (2018), and Zakataeva et al., “Wild-type and feedback-resistant phosphoribosyl pyrophosphate synthetases from Bacillus amyloliquefaciens: purification, characterization, and application to increase purine nucleoside production,”Appl. Microbiol. Biotechnol., 93: 2023-33 (2012), may be used according to the present invention. In some embodiments, the modifications can include deletion or modification of the gene (pncC) responsible for the conversion of NMN to NaMN, resulting in loss or decrease in enzyme activity. In some embodiments, the modifications can include generation and incorporation of a conditionally active ribonucleotide reductase using a) temperature-sensitive (ts) mutation(s) in the protein coding sequence, b) is self-splicing intein, c) ligand-dependent gene expression, and/or d) ligand-dependent enzyme inactivation. The purpose of the modification is to block cell division and biomass accumulation while maintaining protein synthesis and metabolic activity by inhibiting deoxyribonucleotide synthesis required for DNA production and replication.

Modified Pathway for NMN Production

As shown in FIGS. 2 and 3, NMN production from Nam can be achieved within an engineered host cell through a single enzymatic step involving nicotinamide phosphoribosyl transferase enzyme coded by an nadV gene. In those microorganisms lacking an endogenous gene coding for a phosphoribosyl transferase enzyme such as C. glutamicum, it is necessary to introduce an exogenous gene coding for a phosphoribosyl transferase enzyme using well-known techniques in the field of genetic engineering. In a preferred aspect of the present invention, the source of nadV gene coding for nicotinamide phosphoribosyl transferase enzyme can be selected from the group consisting of Stenotrophomonas maltophilia, Chromobacterium violaceum, Deinococcus radiodurans, Synechocystis sp. PCC 6803. Pseudonocardia dioxanivorans CB1190, Shewanella oneidensis MR-1, and Ralstonia solanacearum GMI1000. In an exemplary embodiment of the present invention, an nadV gene from any one of the foregoing microbial species is isolated and introduced into a strain of Corynebacterium glutamicum using genetic engineering techniques well-known in the art. In a preferred aspect, the exogenous gene nadV is codon optimized before its transfer into a selected microbial host cell to assure optimal expression of the nicotinamide phosphoribosyl transferase enzyme in the microbial host cell.

In the phosphoribosyl transferase mediated enzyme reaction, phosphoribosyl pyrophosphate (PRPP) acts as a co-substrate and it is necessary to make sure that there is a sufficient amount of PRPP available within the cell to facilitate the phosphoribosyl transferase enzyme-mediated reaction. The pool size of PRPP within the microbial may be increased by means of enhancing the expression of the activity of a PRPP synthetase. The enhanced expression of PRPP synthetase activity can be achieved by means of expressing an exogenous gene prsA. In addition, if there is any feedback inhibition on the PrsA enzyme activity, it is preferable to use a prsA gene that encodes a feedback-resistant variant of the PrsA enzyme.

In another embodiment of this invention, as a way of conserving the PRPP pool serving as the co-substrate in the production of NMN from Nam, additional genetic modifications can be introduced to block other pathways utilizing PRPP pool within the cell. In one aspect of the present invention, the pyrE gene is mutated leading to the inactivation of the orotate phosphoribosyl transferase enzyme capable of catalyzing the transfer of a ribosyl phosphate group from PRPP to orotate, which in turn leads to the formation of orotidine.

In order to achieve the production target for NMN production, besides from ensuring that the appropriate phosphoribosyl transferase and phosphoribosyl pyrophosphate (PRPP) synthetase enzymes are present and sufficient amount of PRPP are present within the microbial cell for production of NMN from Nam, it is advantageous to block or inactivate possible NMN utilization/degradation pathways within the microbial cell.

For example, the microbial host cell selected for producing NMN using Nam as a feedstock and having a codon optimized exogenous gene coding for nicotinamide phosphoribosyl transferase enzyme can further comprise additional genetic modifications to ensure the conservation of the NMN produced within the cell, wherein the additional genetic modifications block other biochemical pathways that consume NMN. In one aspect of this embodiment, the ushA gene coding for an enzyme capable of the conversion of NMN to NR is deleted. In another aspect of this embodiment, the gene pncC is deleted resulting in the loss of nicotinamide-nucleotide amidohydrolase enzyme activity capable of the conversion of NMN into nicotinate mononucleotide (NAMN). In yet another aspect of this invention, the genes cgl1364, cgl1977 and cgl2835 are deleted leading to the elimination of a putative nucleosidase capable of the conversion of NMN into Nam and ribose-5 phosphate. In another aspect of this invention, the gene nadD is genetically modified so that the activity of the enzyme capable of the conversion of NMN to NAD is blocked.

Accordingly, in one aspect, the present invention provides methods of producing NMN, wherein such method comprises: feeding nicotinamide to a culture of a genetically modified Corynebacterium glutamicum strain, where said strain comprises at least one genetic modification selected from the group consisting of: (a) heterologous expression of a gene encoding nicotinamide phosphoribosyltransferase capable of the conversion of Nam to NMN; (b) deletion or modification of one or more genes capable of the enzymatic conversion of Nam to NA; (c) deletion or modification of one or more genes capable of the enzymatic conversion of NMN to NR; (d) modification of one or more genes capable of producing PRPP; (e) modification or deletion of PRPP-requiring biochemical pathways other than the biochemical pathway for the conversion of Nam to NMN; (f) deletion or modification of a gene capable of the enzymatic conversion of NMN to NAMN; (g) deletion or modification of a gene capable of the conversion of NMN to NAD; (h) deletion or modification of one or more genes coding for a promiscuous nucleosidase reaction capable of the conversion of NMN to Nam and ribose-5-phosphate; (i) incorporation of a conditionally active ribonucleotide reductase to block cell division and biomass accumulation without affecting protein synthesis and normal metabolic activity; and (j) any combinations thereof. In various embodiments, the present genetically modified strain with said at least one modification produces an increased amount of NMN compared to a strain without any of said modifications.

Modified Pathway for NAD Production

In yet another embodiment, the present invention provides a method for producing NAD using Nam as a feedstock. In one aspect of this embodiment, the microbial host cell selected for producing NMN using Nam and having a codon optimized exogenous gene coding nicotinamide phosphoribosyl transferase enzyme can further comprise an additional genetic modification in the nadD gene yielding an upregulated NAD(+) synthetase enzyme capable of the conversion of NMN to NAD. In yet another aspect of this embodiment, the gene nudC is mutated so that enzyme capable of the conversion of NAD back to NMN is blocked.

Accordingly, in yet another aspect, the present invention provides methods of producing NAD, wherein such method comprises: feeding nicotinamide to a culture of a genetically modified Corynebacterium glutamicum strain, where said strain comprises at least one genetic modification selected from the group consisting of: (a) heterologous expression of a gene encoding a nicotinamide phosphoribosyltransferase capable of the conversion of Nam to NMN; (b) deletion or modification of one or more genes capable of the enzymatic conversion of Nam to NA; (c) deletion or modification of one or more genes capable of the enzymatic conversion of NMN to NR; (d) modification of one or more genes capable of producing PRPP; (e) modification or deletion of PRPP requiring biochemical pathways other than the biochemical pathway for the conversion of Nam to NMN; (f) deletion or modification of the gene capable of the enzymatic conversion of NMN to NAMN; (g) modification of the gene capable of the conversion of NMN to NAD; (h) deletion or modification of one or more genes capable of the conversion of NAD back to NMN; (i) deletion or modification of one or more genes coding for a nucleosidase capable of the conversion of NMN to Nam and ribose-5-phosphate; (j) incorporation of a conditionally active ribonucleotide reductase to block cell division and biomass accumulation without affecting protein synthesis and normal metabolic activity; and (k) any combinations thereof. In various embodiments, the present genetically modified strain with said at least one modification produces an increased amount of NMN compared to a strain without any of said modifications.

Modified Pathway for NR Production

In yet another embodiment, the present invention provides a method for producing NR using Nam as a feedstock. In one aspect of this embodiment, the microbial host cell selected for producing NMN using Nam and having a codon optimized exogenous gene coding nicotinamide phosphoribosyl transferase enzyme can further comprise a functionally active dephosphorylation enzyme coded by a ushA gene. In another aspect of this invention, the ushA gene is genetically modified yielding a dephosphorylase enzyme with enhanced activity for the conversion of NMN to NR.

Accordingly, in another aspect, the present invention provides methods of producing NR, wherein such method comprises: feeding nicotinamide to a culture of a genetically modified Corynebacterium glutamicum strain, where said strain comprises at least one genetic modification selected from the group consisting of: (a) heterologous expression of a gene encoding a nicotinamide phosphoribosyltransferase capable of the conversion of Nam to NMN; (b) deletion or modification of one or more genes capable of the enzymatic conversion of Nam to NA; (c) modification of one or more genes capable of the enzymatic conversion of NMN to NR; (d) modification of one or more genes capable of producing PRPP; (e) modification or deletion of PRPP requiring biochemical pathways other than the biochemical pathway for the conversion of Nam to NMN; (f) deletion or modification of the gene capable of the enzymatic conversion of NMN to NAMN; (g) deletion or modification of the gene capable of the conversion of NMN to NAD; (h) deletion or modification of one or more genes coding for a nucleosidase enzyme capable of the conversion of NMN to Nam and ribose-5-phosphate; (i) deletion or modification of one or more genes coding for a nucleosidase enzyme capable of the conversion of NR to Nam and ribose-sugar, (j) incorporation of a conditionally active ribonucleotide reductase to block cell division and biomass accumulation without affecting protein synthesis and normal metabolic activity; and (k) any combinations thereof. In various embodiments, the present genetically modified strain with said at least one modification produces an increased amount of NR compared to a strain without any of said modifications.

Modified Pathway for Increasing NMN Titer

The production of NMN from NAM as catalyzed by the NadV enzyme depends at least in part upon the rate at which microbial host cells produce the PRPP co-substrate. Illustrated in FIG. 8 is the oxidative branch of the pentose phosphate pathway (“PPP”) in which D-glucose-6-phosphate is converted to D-ribulose-5-phosphate and then PRPP. A strategy to increase flux through the PPP entails knocking out the pgi gene, thereby redirecting the D-glucose-6-phosphate from glycolysis to the PPP and increasing PRPP availability. However, a problem associated with this approach in Corynabacterium gluamicum is that growth is greatly retarded on minimal media such as CGXII. Without wishing to be bound to any particular theory, it is believed that the native ZWF protein, i.e., the glucose 6-phosphate dehydrogenase enzyme catalyzing the first step of the PPP pathway, is inhibited by ATP and PEP (phosphoenolpyruvate) accumulation during growth on glucose, thereby greatly reducing carbon flux through the PPP. Moreover, assuming that an alternative ZWF can be identified that allows carbon flux to increase, a further problem emerges likely due to the accumulation of redox equivalents in the form of NADPH instead of NADH, and wild-type Corynebacterium lacks a pyridine nucleotide transhydrogenase, e.g. a soluble UdhA or a transmembrane PntAB, to address this shortcoming.

Accordingly, in one aspect, the present invention provides a recombinant Δpgi mutant of Corynebacteriun glutamicum where the expression of a transgenic ZWF enzyme in combination with a pyridine nucleotide transhydrogenase rescues growth while improving production of PRPP as reflected in higher titers of NMN. Hence, in a related aspect, the present invention provides a method of producing NMN, wherein the method comprises: feeding nicotinamide to a culture of a genetically modified Corynebacterium glutamicum strain, wherein said strain comprises genetic modifications including: (a) heterologous expression of a gene encoding nicotinamide phosphoribosyltransferase capable of the conversion of Nam to NMN; (b) deletion or modification of one or more genes capable of the enzymatic conversion of Nam to NA; (c) deletion or modification of one or more genes capable of the enzymatic conversion of NMN to NR; (d) modification of one or more genes capable of producing PRPP; (e) modification or deletion of PRPP-requiring biochemical pathways other than the biochemical pathway for the conversion of Nam to NMN; (f) deletion or modification of a gene capable of the enzymatic conversion of NMN to NAMN; (g) deletion or modification of a gene capable of the conversion of NMN to NAD; (h) deletion or modification of one or more genes coding for a promiscuous nucleosidase reaction capable of the conversion of NMN to Nam and ribose-5-phosphate; (i) deletion or modification of a gene capable of the enzymatic conversion of D-glucose-6-phosphate to D-fructose-6-phosphate; (j) incorporation of a recombinant ZWF; (k) incorporation of a recombinant pyridine nucleotide transhydrogenase, where the combination of the recombinant ZWF and the recombinant pyridine nucleotide transhydrogenase allows for compensating the growth defect associated with the deletion or modification of a gene capable of the enzymatic conversion of D-glucose-6-phosphate to D-fructose-6-phosphate; (1) incorporation of a conditionally active ribonucleotide reductase to block cell division and biomass accumulation without affecting protein synthesis and normal metabolic activity; and (m) any combinations thereof.

The production of PRPP is thereby improved as reflected in higher titers of NMN relative to a strain without such modifications.

Nicotinamide compounds (NMN, NR, NAD) produced according to the present disclosure can be utilized in any of a variety of applications, for example, exploiting their biological or therapeutic properties (e.g., controlling low-density lipoprotein cholesterol, increasing high-density lipoprotein cholesterol, etc.). For example, according to the present disclosure, nicotinamide ribose may be used in pharmaceuticals, foodstuffs, and dietary supplements, etc.

The nicotinamide mononucleotide (NMN) produced by the method disclosed in this invention could have therapeutic value in improving plasma lipid profiles, preventing stroke, providing neuroprotection with chemotherapy treatment, treating fungal infections, preventing or reducing neurodegeneration, or in prolonging health and well-being. Thus, the present invention is further directed to the nicotinamide riboside compounds obtained from the genetically modified bacterial cell described above, for treating a disease or condition associated with the nicotinamide riboside kinase pathway of NAD+ biosynthesis by administering an effective amount of a nicotinamide riboside composition.

Diseases or conditions which typically have altered levels of NAD+ or NAD+ precursors or could benefit from increased NAD+ biosynthesis by treatment with nicotinamide riboside include, but are not limited to, lipid disorders (e.g., dyslipidemia, hypercholesterolemia or hyperlipidemia), stroke, neurodegenerative diseases (e.g., Alzheimer's, Parkinsons and Multiple Sclerosis), neurotoxicity as observed with chemotherapies, Candida glabrata infection, and the general health declines associated with aging. Such diseases and conditions can be prevented or treated by diet supplementation or providing a therapeutic treatment regime with a nicotinamide riboside composition.

It will be appreciated that, the nicotinamide compounds isolated from the genetically modified bacteria of this invention can be reformulated into a final product. In some other embodiments of the disclosure, nicotinamide riboside compounds produced by genetically modified host cells as described herein are incorporated into a final product (e.g., food or feed supplement, pharmaceutical, etc.) in the context of the host cell. For example, host cells may be lyophilized, freeze dried, frozen or otherwise inactivated, and then whole cells may be incorporated into or used as the final product. The host cell may also be processed prior to incorporation in the product to increase bioavailability (e.g., via lysis).

In some embodiments of the disclosure, the produced nicotinamide riboside compounds are incorporated into a component of food or feed (e.g., a food supplement). Types of food products into which nicotinamide riboside compounds can be incorporated according to the present disclosure are not particularly limited, and include beverages such as milk, water, soft drinks, energy drinks, teas, and juices; confections such as jellies and biscuits; fat-containing foods and beverages such as dairy products; processed food products such as rice, bread, breakfast cereals, or the like. In some embodiments, the produced nicotinamide riboside compound is incorporated into a dietary supplement, such as, for example, a multivitamin.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure belongs. Although any methods and materials similar to or equivalent to those described herein can be used in the practice or testing of the present disclosure, the preferred materials and methods are described below.

The disclosure will be more fully understood upon consideration of the following non-limiting Examples. It should be understood that these examples, while indicating preferred embodiments of the subject technology, are given by way of illustration only. From the above discussion and these examples, one skilled in the art can ascertain the essential characteristics of the subject technology, and without departing from the spirit and scope thereof, can make various changes and modifications of the subject technology to adapt it to various uses and conditions.

EXAMPLES
Example 1
Strain Construction

Various engineered C. glutamicum strains were constructed with one or more genetic modifications as described in Table 5. In carrying out the genetic deletions in C. glutamicum summarized in Table 5, pDEL plasmids (a suicidal plasmid which lacks an origin of replication for C. glutamicum) were used. The pDEL plasmid contained homologous regions (approximately 500-800 bps each) upstream and downstream of the gene targeted for deletion. As shown in FIG. 5, the upstream and downstream regions flanking the gene targeted for deletion were obtained using PCR and cloned into the pDEL plasmid containing an SacB gene and an antibiotic marker.

C. glutamicum cells were transformed with such plasmids and plated in CASO medium containing kanamycin (25 ug/mL) and left overnight. The resulting colonies were plated in a medium containing 6% sucrose to select for double recombinants which have target gene deletion and does not have any portion of the pDEL plasmid integrated into its chromosomal DNA.

The above engineered strains were subjected to further genetic modifications using plasmids described in Table 6 to introduce an exogenous NadV gene and a prsA gene variant/mutant.

Example 2
NMN Production from Nam

Strains constructed according to Example 1 were grown overnight in a BHI medium containing kanamycin. The cells were pelleted down, washed and resuspended in CGXI1 medium for 2-3 hrs for recovery as the C. glutamicum cells have a long lag phase when moved from one medium to another medium. To start the fermentation assay, cells were inoculated in a CGXII medium (Table 7) at 0.2 OD₆₀₀, at 30° C. and kept on a rotary shaker (250 rpm). The cells were induced with 0.4 mM IPTG when cell density reaches 0.6-0.8 OD₆₀₀. Nam was fed to the cell culture, and samples were collected every 24 h for up to 72 h to confirm NMN production.

Specifically, samples were obtained from the culture supernatant and centrifuged at 0.4000× G for 5 minutes. The clear supernatant was mixed with equal volume of methanol, vortexed for 30 seconds or shaken at 600 rpm on a plate shaker for 10 minutes and centrifuged at >4000× G for 5 minutes to remove any additional debris and the resultant supernatant was analyzed by HPLC method using a Phenomenex Luna 3 μm NH2 100 Å operating in HILAC mode with a maximum pressure of 400 Barr. 2 μL injections were monitored at 261 nm with standard curves generated using standards of NAM, NR, NMN, and NAD+. The aqueous buffer was 5 mM ammonium acetate pH 9.9 (A) while the organic buffer was acetonitrile (B). The HPLC column was run at 0.1 mL/min with the following gradient: 0 min-95% B, 1 min-95% B, 15 min-0% B, 20 min-0% B, 20.01 min-95% B, 30 min-95% B.

The production titers of NMN by the NMN4 and NR5 strains (both containing exogenous genes smaOP and prsA L136I), respectively, are shown in FIG. 6.

The production titers of NMN by an NMN3 strain containing exogenous genes cviHA and prsA L136I, an NMN4 strain containing exogenous genes cviHA and prsA L136I, an NMN4 strain containing exogenous genes smaOP and prsA L136I, and an NR5 strain containing exogenous genes smaOP and prsA L136I, respectively, are shown in FIG. 7.

As shown in FIG. 6 and FIG. 7, the NR5 strain characterized by the deletion of endogenous genes cgl1364 coding for purine nucleosidase iunH3, cgl1977 coding for purine nucleosidase iunH2, and cgl2835 for purine nucleosidase iunH1 appears to have the highest NMN production titers. Without wishing to be bound by any particular theory, it is believed that deletion of one or more of the foregoing genes can lead to a significant decrease in the degradation of NMN back into nicotinamide (Nam) and ribose-5P. This observation was highly surprising given the fact that the deletion of one of more of cgl1364, cgl1977, and cgl2835 was previously known only to have the effect of reducing the degradation of NR into NA and ribose.

Example 3
Growth Rescue and Increase in the PPP Pathway

As anticipated above, the pgi gene may be knocked out to redirect the D-glucose-6-phosphate away from glycolysis and into the PPP, thereby increasing PRPP availability. However, the Δpgi mutant of C. glutamicum is negatively affected by greatly impaired growth. Without being bound to any particular theory, it is believed that the native ZWF protein, i.e., the glucose 6-phosphate dehydrogenase enzyme catalyzing the first step of the PPP pathway, is inhibited by ATP and PEP (phosphoenolpyruvate) accumulation during growth on glucose, thereby greatly reducing carbon flux through the PPP.

Three recombinant ZWFs were screened for their ability to overcome the inhibition displayed by native C. glutamicum ZWF: (i) a feedback resistant mutant (A243T) of C. glutamicum ZWF (SEQ ID NO: 28); (ii) an engineered mutant (R46E/Q47E) of the ZWF from Leuconostoc mesenteroides (lmZWF, SEQ ID NO: 32) which has mixed use of NADH and NADPH; and (iii) the ZWF from Zymomonas mobilis (zmZWF) which favors NADH use.

Two transhydrogenases were screened for their ability to overcome NADPH accumulation: (i) UdhA from E. coli is a soluble transhydrogenase that is reported to favor the reduction of NAD+ by NADPH; and (ii) PntAB from E. coli is a membrane-bound transhydrogenase that is reported to favor the reduction of NADP+ by NADH.

The recombinant ZWFs and the transhydrogenase were paired in the cgDVS expression vector in constitutively expressed or cumate-induced configurations, as follows:

Constitutive Expression:

- (i) cgDVS.pSOD.lmZWF.pntAB (S.lmZWF.pntAB)
- (ii) cgDVS.pSOD.lmZWF.udhA (S.lmZWF.udhA)
- (iii) cgDVS.pSOD.zmZWF.pntAB (S.zmZWF.pntAB)
- (iv) cgDVS.pSOD.zmZWF.udhA (S.zmZWF.udhA)

Cumate-Induced Expression:

- (v) cgDVS.pCT5.cgZWF*.udhA (S.pCT5.cg.udhA)

The above vectors (i)-(v) were each independently transformed into the “BASE” strain, i.e., the NMN11 strain previously transformed with the cgDVK.ptac.smaOP.prsA vector. The BASE strain was also transformed with either of two control vectors cgDVS expressing red fluorescent protein mCherry from either the min3 constitutive promoter (S.min3.mCH) or the pCT5-induced promoter (S.pCT5.mCH). The transformed strains were then grown on CGXII medium to identify instances of successful rescue from growth deficit in NMN11.

As illustrated in FIG. 9, where the time is measured in hours on the x-axis and the OD₆₀₀is shown on the y-axis, the BASE strain, min3.mCherry and pCT5.mCherry exhibited almost zero growth, as expected. The pCT5.mCherry strain eventually emitted a signal at a wavelength of 630 nm, but still showed no major visible growth or mCherry concentration by visual examination, which would explain the later rise in emission at 630 nm as mCherry is still absorbing in the vicinity of such wavelength. The zmZWF.udhA (dark blue) and lmZWF.PntAB (yellow) strains exhibited the best rescues of the growth defect. The second-best results were obtained from lmZWF.udhA, while zmZWF.pntAB showed a modest early growth that trailed off. Initial production tests carried out in flasks revealed that strain zmZWF.udhA produced the most NMN.

The following strains were transformed with the vectors as indicated:

- NMN4: Δcgl1777-8 Δcgl2487 Δcgl1963 Δcgl0328 Δcgl2773
  - (1) No control: cgDVK.ptac.mcherry (mCherry)
  - (2) Production control: cgDVK.ptac.smaOP.prsA (K.smaOP.PRS)
- NMN13: Δcgl1777-8 Δcgl2487 Δcgl963 Δcgl0328 Δcgl0851
  - (3) cgDVK.ptac.smaOP.prsA
  - (4) cgDVK.ptac.smaOP.prsA+cgDVS.pSOD.zmZWF.udhA (S.ZWF.udhA)
- NMN11: Δcgl1777-8 Δcgl2487 Δcgl9%3 Δcgl0328 Δcgl0851 Δcgl2773
  - (5) cgDVK.ptac.smaOP.prsA
  - (6) cgDVK.ptac.smaOP.prsA+cgDVS.pSOD.zmZWF.udhA

Two strains were also manufactured with the pSOD.zmZWF.udhA construct inserted into the pgi location to do away with the need for cgDVS and the spectinomycin antibiotic:

- NMN29: Δcgl1777-8 Δcgl2487 Δcgl1963 Δcgl0328 Δcgl0851: pSODzmZWF.udhA
  - (7) cgDVK.ptac.smaOP.prsA
- NMN30: Δcgl1777-8 Δcgl2487 Δcgl1963 Δcgl0328 Δcgl0851: pSODzmZWF.udhA Δcgl2773
  - (8) cgDVK.ptac.smaOP.prsA

The amount of NMN produced by each strain was assessed after 48 hours and 72 hours of cell culture growth, respectively. The results are illustrated in FIG. 10.

TABLE 1

Genes and enzymes used in the present invention

Corynebacterium

Gene

glutamicum ATCC 13032

EC

name
NCBI gene symbol
Name of the enzyme
Number

pncA
NCgl2401
Nicotinamidase/
3.5.1.19

pyrazinamidase

prs
NCgl0905
Ribose-phosphate
2.7.6.1

pyrophosphokinase or

PRPP synthase

pncB
NCgl2431
Nicotinate
6.3.4.21

phosphoribosyltransferase

pncC
NCgl1888
Nicotinamide-nucleotide
3.5.1.42

amidohydrolase

nadD
NCgl2270
Nicotinate-nucleotide
2.7.7.18

adenylyltransferase

nadE
NCgl2446
NH(3)-dependent
6.3.1.5

NAD(+) synthetase

nudC
NCgl0744
NADH pyrophosphatase
3.6.1.22

cgl0328
NCgl0322
5-nucleotidase
3.1.3.5

cgl1364
NCgl1309
Nicotinamide riboside
3.2.2.1

hydrolase

nadV
Not present in
Nicotinamide
2.4.2.12

Corynebacterium

phosphoribosyltransferase

glutamicum ATCC 13032.

TABLE 2

Preferred sources and genes for nadV coding for nicotinamide

phosphoribosyltransferase activity

Source of nadV gene
NCBI gene ID

Chromobacterium violaceum ATCC 12472
CV_RS00140

Deinococcus radiodurans R1
DR_0294

Synechocystis sp. PCC 6803
slr0788

Pseudonocardia dioxanivorans CB1190
Psed_2146

Shewanella oneidensis MR-1
SO_1981

Ralstonia solanacearum GMI1000
RSp0836

Stenotrophomonas maltophilia

B2FI76

Haemophilus ducreyi

NAMPT gene

TABLE 3

Additional genes and proteins used in the present invention

Gene

Accession

Gene
Number:
Protein
Details

cviHA
AAQ57714
cviNadVha
Codon harmonized variant of the

nicotinamide

phosphoribosyltransferase (NadV)

from Chromobacterium violaceum

smaOP
SQG65624
smaNadVop
Codon optimized variant of the

nicotinamide

phosphoribosyltransferase (NadV)

from Stenotrophomonas maltophilia

prsA

PrsA (PRS)
Codon optimized variant of the

PRPP synthase from

Corynebacterium
glutamicum

ATCC 13032

prsA

PrsA L136I
Feedback resistant mutant of PrsA

L136I

(PRS

L136I)

zmZWF

zmZWF
Codon optimized variant of the

glucose-6-phosphate dehydrogenase

from Zymomonas mobilis strain

ATCC 10988, Zmob_0908

lmZWF

lmZWF
Codon optimized mutant

R46E/Q47E
(R46E/Q47E) of the glucose-6-

phosphate dehydrogenase from

Leuconoston mesenteroides

cgZWF*

cgZWF
Codon optimized mutant (A243T)

A243T
of the of the glucose-6-phosphate

dehydrogenase from

Corynebacterium
glutamicum

udhA

udbA
Soluble Pyridine Nucleotide

Transhydrogenase from Escherichia

coli

pntAB

pntA.B
Membrane-bound Pyridine

Nucleotide Transhydrogenase from

Escherichia
coli

TABLE 4

Sequence Information

SEQ ID No. 1
PRT; Chromobacterium violaceum; nicotinamide

phosphoribosyltransferase-cviNadVha (cviHA)

SEQ ID No. 2
PRT; Stenotrophomonas maltophilia; nicotinamide

phosphoribosyltransferase-smaNadVop (smaOP)

SEQ ID No. 3
PRT; codon-optimized PRPP synthase variant, CYL77_RS04805-prsA

(PRS)

SEQ ID No. 4
PRT; feedback resistant PRPP synthase mutant, prsA L136I (PRS

L136I)

SEQ ID No. 5
DNA; nicotinamidase pncA (CGL_RS12350, ncgl2401, cgl2487

SEQ ID No. 6
PRT; nicotinamidase pncA (CGL_RS12350, ncgl2401, cgl2487

SEQ ID No. 7
DNA; Nicotinamide-nucleotide amidohydrolase pncC (CGL_RS09770,

ncgl1888, cgl1963)

SEQ ID No. 8
PRT; Nicotinamide-nucleotide amidohydrolase pncC (CGL_RS09770,

ncgl1888, cgl1963)

SEQ ID No. 9
DNA; restriction modification system; RM = cgl1777

(CYL77_RS08985)

SEQ ID No. 10
PRT; restriction modification system; RM = cgl1777 (CYL77_RS08985)

SEQ ID No. 11
DNA; restriction modification system; RM = cgl1778

(CYL77_RS08990)

SEQ ID No. 12
PRT; restriction modification system; RM = cgl1778 (CYL77_RS08990)

SEQ ID No. 13
DNA; orotate phosphoribosyltransferase pyrE; CGL_RS13820,

ncgl2676

SEQ ID No. 14
PRT; orotate phosphoribosyltransferase pyrE; CGL_RS13820,

ncgl2676, cgl2773

SEQ ID No. 15
DNA; 5′-nucleotidase ushA; cgl0328-CGL_RS01710, ncgl0322,

cg0397

SEQ ID No. 16
PRT; 5′-nucleotidase ushA; cgl0328-CGL_RS01710, ncgl0322, cg0397

SEQ ID No. 17
DNA; nicotinamide ribose transporter pnuC; ncgl0063, CGL_RS00355,

cgl0064

SEQ ID No. 18
PRT; nicotinamide ribose transporter pnuC; ncgl0063, CGL_RS00355,

cgl0064

SEQ ID No. 19
DNA; purine nucleosidase iunH3; cgl1364 (CGL_RS06810, ncgl1309,

cgl543, iunH3)

SEQ ID No. 20
PRT; purine nucleosidase iunH3; cgl1364 (CGL_RS06810, ncgl1309,

cg1543, iunH3)

SEQ ID No. 21
DNA; purine nucleosidase iunH2; cgl1977 (cg2168, iunH2,

CYL77_RS09970)

SEQ ID No. 22
PRT; purine nucleosidase iunH2; cgl1977 (cg2168, iunH2,

CYL77_RS09970)

SEQ ID No. 23
DNA; purine nucleosidase iunH1; cgl2835 (cg3137, iunH1,

CYL77_RS14340)

SEQ ID No. 24
PRT; purine nucleosidase iunH1; cgl2835 (cg3137, iunH1,

CYL77_RS14340)

SEQ ID No. 25
DNA; glucose-6P isomerase pgi; cgl0851 (ncgl0817)

SEQ ID No. 26
PRT; glucose-6P isomerase PGI; cgl0851 (ncgl0817)

SEQ ID No. 27
DNA; codon-optimized mutant (A243T) of the of the glucose-6-

phosphate dehydrogenase from Corynebacterium glutamicum; cgZWF

SEQ ID No. 28
PRT; codon-optimized mutant (A243T) of the of the glucose-6-

phosphate dehydrogenase from Corynebacterium glutamicum; cgZWF

SEQ ID No. 29
DNA; glucose-6-phosphate dehydrogenase of

Leuconoston.mesenteroides, codon optimized mutant (R46E/Q47E) of

the gene having accession number M64446.1; lmZWF

SEQ ID No. 30
RNA; glucose-6-phosphate dehydrogenase of

Leuconoston.mesenteroides, codon optimized mutant (R46E/Q47E);

lmZWF

SEQ ID No. 31
DNA; codon-optimized variant of the glu6-phosphate dehydrogenase

from Zymomonas mobilis strain ATCC 10988, Zmob_0908

SEQ ID No. 32
PRT; codon-optimized variant of the glu6-phosphate dehydrogenase

from Zymomonas mobilis strain ATCC 10988, NCBI-ProteinID:

AEH62743.1

SEQ ID No. 33
DNA; soluble Pyridine Nucleotide Transhydrogenase from Escherichia

coli; udhA NP_418397.2, EG11428

SEQ ID No. 34
PRT; soluble Pyridine Nucleotide Transhydrogenase from Escherichia

coli; udhA AAC76944

SEQ ID No. 35
DNA; “A” subunit of Membrane bound Pyridine Nucleotide

Transhydrogenase (pntA) from Escherichia coli MG1655; ECK1598,

variant g1342a, NP_416120.1

SEQ ID No. 36
PRT; “A” subunit of Membrane bound Pyridine Nucleotide

Transhydrogenase (pntB) from Escherichia coli; P07001.2 A434T

variant

SEQ ID No. 37
DNA; “B” subunit of Membrane bound Pyridine Nucleotide

Transhydrogenase (pntB) from Escherichia coli MG1655; ECK1597,

NP_416119.1

SEQ ID No. 38
PRT; “B” subunit of Membrane bound Pyridine Nucleotide

Transhydrogenase (pntB) from Escherichia coli; P0AB69.1

TABLE 5

Strains constructed according to the present invention

Strain name
Genotype/Description of genetic modification

ATCC 13032

Corynebacterium glutamicum ATCC 13032

Cgl1
ATCC 13032 Δcgl1777 Δcgl1778-Deletion of restriction

modification (RM) system

NMN1
Cgl1 Δcgl2487-Deletion of nicotinamidase (pncA) to

prevent conversion of NA to NAM

NMN2
NMN1 Δcgl1963-Deletion of nicotinamide-nucleoside

amidase (pncC) to prevent conversion of NMN to NaMN.

NMN3
NMN2 Δcgl0328-Deletion of 5′-nucleotidase (ushA) to

prevent conversion of NMN to NR.

NMN4
NMN3 Δcgl2773-Deletion of orotate

phosphoribosyltransferase (pyrE) to prevent conversion

of PRPP to Orotidine-5-P; Uracil auxotroph.

ΔRM ΔpncA ΔpncC ΔushA ΔpyrE

NR1
NMN2 Δcgl1364-deletion of purine nucleosidase (iunH3)

to prevent conversion of NR to NAM.

NR2
NR1 Δcgl0064-Deletion of nicotinamide ribose

transporter (pnuC) to inhibit NR uptake

NR3
NR2 Δcgl2835-Deletion of purine nucleosidase (iunH1)

to prevent conversion of NR to NAM

NR5
NR3 Δcgl1977-deletion of purine nucleosidase (iunH2) to

prevent conversion of NR to NAM

ΔRM (9, 11) ΔpncA (5) ΔpncC (7) ΔpnuC (17) Δcgl1364

Δcgl1977 Δcgl2835 (19, 21, 23)

NMN11
NMN4 Δcgl0851-Deletion of glucose-6P isomerase

(PGI) to push carbon flux towards PPP

NMN13
NMN3 Δcgl0851-Deletion of glucose-6P isomerase

(PGI) to push carbon flux towards PPP

NMN16
NR5 Δcgl0328-Deletion of 5′-nucleotidase (ushA) to

prevent conversion of NMN to NR

NMN17
NMN16 Δcgl2773-Deletion of orotate

phosphoribosyltransferase (pyrE) to prevent conversion

of PRPP to Orotidine-5-P; Uracil auxotroph

NMN29
NMN11 Δcgl0851:zmZWF.udhA-Insertion of

zmZWF.udhA into PGI locus to increase carbon

flux towards PPP

NMN30
NMN13 Δcgl0851:zmZWF.udhA-Insertion of

zmZWF.udhA into PGI locus to increase carbon

flux towards PPP

TABLE 6

Plasmids for introducing exogenous genes

Plasmid Code
Plasmid Name
Description

cgDVK

E. coli/C. glut. Shuttle vector

ColE1 ori/pHM1519 ori KanR

cviHA.prsA(L136I)
cgDVK.pTAC.cviHA.prsA(L136I)
cgDVK constitutive LacI

production, IPTG induced

expression of cviNadVha and

PrsA(L136I)

smaOP.prsA(L136I)
cgDVK.pTAC.smaOP.prsA(L136I)
cgDVK constitutive LacI

production, IPTG induced

expression of smaNadVop and

PrsA(L136I)

cgDVS

E. coli/C. glut shuttle vector

pBL1/ori SpecR

zmZWF.udhA
cgDVS.pSOD.zmZWF.udhA
cgDVS constitutive pSOD

expression of zmZWF.udhA

zmZWF.pntAB
cgDVS.pSOD.zmZWF.pntAB
cgDVS constitutive pSOD

expression of zmZWF.pntAB

lmZWF.udhA
cgDVS.pDOS.lmZWF.udbA
cgDVS constitutive pSOD

expression of lmZWF.udhA

lmZWF.pntAB
cgDVS.pSOD.lmZWF.pntAB
cgDVS constitutive pSOD

expression of lmZWF.pntAB

cgZWF*.udhA
cgDVS.pCT5.cgZWF*.udhA
cgDVS constitutive CymR,

Cumate induced expression of

cgZWF*.udhA

TABLE 7

Chemical Composition of CGXII

Growth medium

Component
Conc./L

NH₄SO₄
20 g

KH₂PO₄
1 g

K₂HPO₄
1 g

Urea (300 gl)
5 g

MgSO₄* 7H₂O (1M)
0.25 g

CaCl₂*2H₂O (1M)
10 mg

CG TE 50x
See paper

PCA (50 gl in 57% etoh)
30 mg

Biotin (10 gl)
0.2 mg

Thiamine HCl (20 gl)
1 mg

MOPS
42 g

Glucose (50%)
30 g

Sequences of Interest

SEQ ID NO: 1; PRT; Chromobacterium violaceum; nicotinamide

phosphoribosyltransferase-cviNadVha (cviHA)

MTAPKAAQDKNQLVPFNLADFYKTGHPAMYPRETTRLVANFTPRSAKYAQVLPQLF

DDKVVWFGLQGFIQEYLIDLFNREFFQRPKADAVRRYQRRMDTALGAGAVDGGRLE

ALHDLGHLPLEIRSLPEGARVDIKVPPVTFSNTHPDFPWVATYFETLFSCESWKPSTVA

TIAFEFRKLLSYFAALTGAPQDFVAWQGHDFSMRGMSGVHDAMRCGAGHLLSFTGT

DTIPALDYLEDHYGADAERELVGGSIPASEHSVMALRILLTQQRLARMPAHQGLDDK

ALRRLAEREVVREFVTRDYPAGMVSIVSDTFDFWNVLTVIARELKDDIQARRPDALGN

AKVVFRPDSGDPVRILAGYRDDELQFDDAGNCTARDDGRPVSAAERKGAVECLWDIF

GGTVTERGYRVLDSHVGLIYGDSITLPRARDILLRLAEKGYASCNVVFGIGSFVYGMN

SRDTFGYALKAVYAEVAGEAVDIYKDPATDDGTKKSARGLLRVEEENGRYALYQQQ

TPAEAEGGALRPVFRDGELLVKQTLAEIRQRLQASWTCPEAGSIVWNA

SEQ ID NO: 2; PRT; Stenotrophomonas maltophilia; nicotinamide

phosphoribosyltransferase-smaNadVop (smaOP)

MHYLDNLLLNTDSYKASHWLQYPPGTDATFFYVESRGGLHDRTVFFGLQAILKDALA

RPVTHADIDDAAAVFAAHGEPFNEAGWRDIVDRLGGHLPVRIRAVPEGSVVPTHQAL

MTIESTDPAAFWVPSYLETLLLRVWYPVTVATISWHARQTIAAFLQQTSDDPQGQLPF

KLHDFGARGVSSLESAALGGAAHLVNFLGTDTVSALCLARAHYHAPMAGYSIPAAEH

STITSWGREREVDAYRNMLRQFGKPGSIVAVVSDSYDIYRAISEHWGTTLRDDVIASG

ATLVIRPDSGDPVEVVAESLRRLDEAFGHAINGKGYRVLNHVRVIQGDGINPDTIRAIL

QRITDDGYAADNVAFGMGGALLQRLDRDTQKFALKCSAARVEGEWIDVYKDPVTDA

GKASKRGRMRLLRRLDDGSLHTVPLPANGDDTLPDGFEDAMVTVWENGHLLYDQRL

DDIRTRAAVGH

SEQ ID NO: 3; PRT; Codon-optimized PRPP synthase variant,

CYL77_RS04805-prsA (PRS)

MTAHWKQNQKNLMLFSGRAHPELAEAVAKELDVNVTPMTARDFANGEIYVRFEESV

RGSDCFVLQSHTQPLNKWLMEQLLMIDALKRGSAKRITAILPFYPYARQDKKHRGREP

ISARLIADLMLTAGADRIVSVDLHTDQIQGFFDGPVDHMHAMPILTDHIKENYNLDNIC

VVSPDAGRVKVAEKWANTLGDAPMAFVHKTRSTEVANQVVANRVVGDVDGKDCV

LLDDMIDTGGTIAGAVGVLKKAGAKSVVIACTHGVFSDPARERLSACGABEVITTDTL

PQSTEGWSNLTVLSIAPLLARTINEIFENGSVTTLFEGEA

SEQ ID NO: 4; PRT; Feedback resistant PRPP synthase mutant,

prsA L136I (PRS L136I)

MTAHWKQNQKNLMLFSGRAHPELAEAVAKELDVNVTPMTARDFANGEIYVRFEESV

RGSDCFVLQSHTQPLNKWLMEQLLMIDALKRGSAKRITAILPFYPYARQDKKHRGREP

ISARLIADLMLTAGADRIVSVDIHTDQIQGFFDGPVDHMHAMPILTDHIKENYNLDNIC

VVSPDAGRVKVAEKWANTLGDAPMAFVHKTRSTEVANQVVANRVVGDVDGKDCV

LLDDMIDTGGTIAGAVGVLKKAGAKSVVIACTHGVFSDPARERLSACGAEEVITTDTL

PQSTEGWSNLTVLSIAPLLARTINEIFENGSVTTLFEGEA

SEQ ID NO.: 5; DNA; Nicotinamidase pncA (CGL_RS12350,

ncgl2401, cgl2487)

ATGGCACGCGCACTCATTCTGGTTGATGTTCAAAAAGACTTCTGCCCCGGTGGCAG

CCTAGCCACCGAACGAGGCGATGAAGTGGCGGGAAAAATCGGTGCCTATCAGCTG

TCCCACGGCTCAGAGTACGACGTCGTTGTGGCGACCCAAGATTGGCACATCGATC

CAGGCGAGCACTTTTCAGAAACCCCAGACTTTAAAAACTCCTGGCCAATCCACTGC

GTCGCGGATTCCGATGGTGCCGCCATGCATGACCGCATCAACACCGATTCAATCG

ATGAGTTCTTCCGCAAAGGCCATTACACCGCGGCGTATTCCGGGTTCGAGGGAACT

GCAGTCAGTGAAGAACTCCTCATGTCTCCATGGCTGAAGAACAAGGGAGTCACTG

ATGTAGACATCGTAGGGATCGCTACGGATCACTGCGTTCGAGCCACAGCACTTGA

TGCTCTCAAGGAGGGCTTCAACGTCTCCATTTTGACGTCGATGTGTTCTGCGGTGG

ATTTCCATGCGGGAGACCACGCTTTGGAGGAACTACATGAAGCCGGGGCGATTCT

GATTTAA

SEQ ID No.: 6; PRT; Nicotinamidase pncA (CGL_RS12350,

ncgl2401, cgl2487)

MARALILVDVQKDFCPGGSLATERGDEVAGKIGAYQLSHGSEYDVVVATQDWHIDP

GEHFSETPDFKNSWPIHCVADSDGAAMHDRINTDSIDEFFRKGHYTAAYSGFEGTAVS

EELLMSPWLKNKGVTDVDIVGIATDHCVRATALDALKEGFNVSILTSMCSAVDFHAG

DHALEELHEAGAILI

SEQ ID NO: 7; DNA; Nicotinamide-nucleotide amidohydrolase

pncC (CGL_RS09770, ncgl1888, cgl1963)

ATGTCGGAGAATCTGGCGGGGCGAGTGGTGGAGCTGTTGAAATCGCGCGGTGAAA

CGCTGGCGTTTTGTGAATCCCTCACCGCCGGCCTTGCCAGTGCGACGATCGCAGAG

ATCCCCGGCGCCTCAGTGGTACTTAAAGGCGGGCTGGTCACCTATGCCACCGAGCT

TAAGGTTGCGCTTGCCGGTGTGCCGCAGGAGCTTATCGACGCGCACGGCGTTGTTT

CCCCGCAGTGCGCCCGTGCGATGGCAACGGGGGCCGCACACAGATGCCAGGCAGA

TTGGGCGGTTTCGCTCACGGGCGTTGCTGGCCCCAGCAAACAAGATGGTCATCCG

GTGGGGGAAGTGTGGATCGGAGTGGCTGGTCCTGCGCATTTTGGGGCGTCGGGAA

CAATTGACGCGTATCGTGCGTTTGAAAGTGAACAACAGGTAATATTGGCTGAATT

GGGACGGCATCATATTAGAGAGTCTGCTGTGCAGCAAAGCTTTCGCCTGCTGATTG

ACCATATTGAGTCGCAGTGA

SEQ ID NO: 8; PRT; Nicotinamide-nucleotide amidohydrolase

pncC (CGL_RS09770, ncgl1888, cgl1963)

MSENLAGRVVELLKSRGETLAFCESLTAGLASATIAEIPGASVVLKGGLVTYATELKV

ALAGVPQELIDAHGVVSPQCARAMATGAAHRCQADWAVSLTGVAGPSKQDGHPVG

EVWIGVAGPAHFGASGTIDAYRAFESEQQVILAELGRHHIRESAVQQSFRLLIDHIESQ

SEQ ID No.: 9; DNA; Restriction modification system;

RM = cgl1777 (CYL77_RS08985)

ATGAAGCCCACCGTTAATGTTGTGTTCAATGCGCATCACCCCAAAGATACGCAGCC

GTTGGATAAGTTCTTCGATAAAGAACTTAAAGACACACATCATCTCGATATAACG

GTGGGTTATATCAGTGAGAAATCACTACAATATTTGCTTCTTATTGCAGGCACTCA

CCCCGACCTCACCATCACACTCACCTGTGGAATGCACGCTCGTGAAGGCATGACTG

CTGCCCAACTGCATCATGCGCGAGTGCTCCATGACTACTTAAGCGACCATGATCGA

GGCGGGGTGTTCGTTATTCCCCGATTGCGTTATCACGGCAAAATCTATCTTTTCCA

CAAGAACCAGCACACAGATCCTATTGCTTATATCGGTAGCGCTAACCTCTCAGCCA

TCGTTCCTGGGTACACCTCTACATTCGAGACCGGCGTCATCTTAGACCCCGCACCT

GAAGATCTCGTGCTTCATCTCAACCGTGATGTCGTACCCCTATGTGTCCCCATTGA

CACCGCGCATGTCCCCATCATTAAAGATCAAGAATCCCCGATGAAGCACGTCGCT

GAAGCAACAGCTGTGTCCACCTCTGATGTTGTTGCCATCATGTCCAGCCCATTTAC

TTATAGTTTTGACCTTAAACTCAAAGCCACTGCCAGCAGCAACCTCAATGCTCATA

ACTCAGGCGGTGGCGCGCGCAAACAGAAAAACGGTAGCTTCCTTGCACGCAATTG

GTATGAGGGCGAAATCATTGTCGGTGTCGAGACAACAAGACTCCCAGGTTACCCA

CAAAACAAATCCGAATTCACTGCGGTCACTGATGACGGCTGGTCATTTGTTTGCAA

AATCAGCGGAGGAAACGGAAAGAACCTACGCAGCAAAGGTGACCTGTCCATCCTC

GGTACGTGGTTAAAGTCTCGATTCATTGAACAAGGTGCCCTGGAATACGGCGAGG

ATGCCACCCAAGAAAACATCGACCGTTTTGGGAGAACACATATGACCATGCGCTA

TCACCCAGATTTCGATGTGTGGTCATTCGATCTCAGCCAAACCCCGAAGCCTTCGA

CACAGATTGGGCAGGATTAA

SEQ ID NO: 10; PRT; Restriction modification system;

RM = cgl1777 (CYL77_RS08985)

MKPTVNVVFNAHHPKDTQPLDKFFDKELKDTHHLDITVGYISEKSLQYLLLIAGTHPD

LTITLTCGMHAREGMTAAQLHHARVLHDYLSDHDRGGVFVIPRLRYHGKIYLFHKNQ

HTDPIAYIGSANLSAIVPGYTSTFETGVILDPAPEDLVLHLNRDVVPLCVPIDTAHVPIIK

DQESPMKHVAEATAVSTSDVVAIMSSPFTYSFDLKLKATASSNLNAHNSGGGARKQK

NGSFLARNWYEGEIIVGVETTRLPGYPQNKSEFTAVTDDGWSFVCKISGGNGKNLRSK

GDLSILGTWLKSRFIEQGALEYGEDATQENIDRFGRTHMTMRYHPDFDVWSFDLSQTP

KPSTQIGQD

SEQ ID NO: 11; DNA; Restriction modification system;

RM = cgl1778 (CYL77_RS08990)

RTCACCTCAATAACTACATCACGAGCTTGAGTGATAACGCTGATCTCCGTGAAAAA

GTCACCGCAACCGTAGACGCTTTCCGCCATACCGTCATGGATGACTTCGACTACAT

CAGTGATCAACAAGTCCTGCTTTATGGCGATGTCCAAAGCGGTAAAACCTCACAC

ATGCTGGGAATTATCGCAGATTGCCTCGACAGTACGTTTCACACCATTGTTATTCT

GACCTCGCCTAACACACGGCTCGTGCAACAAACATACGACCGTGTTGCCCAAGCA

TTTCCAGATACTTTGGTGTGCGACCGTGACGGATACAATGATTTCCGTGCGAATCA

AAAGAGCCTCACCCCGCGAAAATCTATCGTAGTCGTCGGAAAAATACCTGCAGTT

CTTGGTAATTGGTTACGCGTCTTTAACGACAGTGGCGCACTTTCTGGACACCCTGT

ACTCATTATTGATGACGAAGCAGATGCGACAAGTCTCAACACCAAAGTAAATCAG

TCTGATGTTTCGACCATTAACCACCAGCTCACTAGCATAAGAGACCTTGCCACAGG

ATGCATCTACCTTCAGGTCACAGGTACACCTCAAGCGGTGCTTCTTCAAAGCGACG

ATAGCAACTGGGCAGCGGAACATGTGCTTCACTTCGCACCTGGTGAGAGCTACAT

CGGTGGTCAACTTTTCTTTTCTGAGCTCAACAACCCTTATCTACGACTTTTCGCTAA

TACCCAATTTGACGAGGATTCTCGCTTCAGCGACGCCATTTACACCTATCTCTTAA

CCGCAGCACTGTTCAAACTTCGCGGTGAAAGCTTGTGTACCATGCTCATTCACCCC

AGCCACACTGCATCCAGTCATAGAGACTTCGCGCAAGAAGCCCGCCTCCAACTCA

CTTTCGCCTTCGAGCGATTCTATGAACCAATGATTCAGCACAATTTCCAACGTGCT

TATGAACAGCTCGCACAAACTGACAGCAACCTGCCACCCTTGAGAAAAATTCTTA

ACATTCTTGGTGGCATGGAAGATGACTTCTCCATCCACATCGTCAATAGCGACAAC

CCGACTGTTGAGGAAGATTGGGCTGATGGTTATAACATTATTGTCGGTGGCAACTC

GCTTGGGCGCGGTTTAACATTCAACAACTTGCAAACCGTTTTCTACGTGCGCGAAT

CCAAGCGACCACAAGCAGACACCCTGTGGCAGCACGCCCGCATGTTTGGCTACAA

ACGCCACAAAGACACCATGCGTGTGTTCATGCCGGCCACTATTGCTCAAACCTTCC

AAGAGGTCTATCTCGGCAACGAAGCTATTAAAAATCAGCTCGATCATGGCACGCA

TATCAACGACATTCGGGTCATTTTAGGTGATGGCGTCGCACCTACTCGTGCCAATG

TTCTCGACAAACGCAAAGTTGGAAACCTCAGCGGTGGCGTCAACTACTTTGCCGCT

GATCCTAGAATCAAGAATGTCGAAGCACTCGACAAAAAACTCTTGGCCTACTTAG

ACAAGCACGGTGAGGACTCCACCATCGGTATGCGCGCGATAATCACCATTCTCAA

CGCCTTTACTGTAGACCCCAACGATCTCGACCTCGCGACCTTCAAGGCTGCGCTCC

TTGACTTTGAACGCAACCAACCTCATCTCACAGCACGTATGGTGCTGCGAACAAAC

CGCAAAGTCAATCAGGGTACAGGCGCCCTGCTCTCCCCTACTGATCAAGCTCTCAG

CCGTGCAGAAGTCGCACACCCATTATTGATCCTATACCGCATTGAAGGTGTTAACG

ATGCTGCTGCGCAACGAGGTGAACCTACGTGGTCAAGCGACCCTATCTGGGTGCC

TAATATTAAACTCCCTGGTCAACGTCAATTCTGGTGCGTAGACGGCTAA

SEQ ID NO: 12; PRT; Restriction modification system;

RM = cgl1778 (CYL77_RS08990)

MSHHTHLNNYITSLSDNADLREKVTATVDAFRHTVMDDFDYISDQQVLLYGDVQSG

KTSHMLGIIADCLDSTFHTIVILTSPNTRLVQQTYDRVAQAFPDTLVCDRDGYNDFRA

NQKSLTPRKSIVVVGKIPAVLGNWLRVENDSGALSGHPVLIIDDEADATSLNTKVNQS

DVSTINHQLTSIRDLATGCIYLQVTGTPQAVLLQSDDSNWAAEHVLHFAPGESYIGGQ

LFFSELNNPYLRLFANTQFDEDSRFSDAIYTYLLTAALFKLRGESLCTMLIHPSHTASSH

RDFAQEARLQLTFAFERFYEPMIQHNFQRAYEQLAQTDSNLPPLRKILNILGGMEDDES

IHIVNSDNPTVEEDWADGYNIIVGGNSLGRGLTFNNLQTVFYVRESKRPQADTLWQH

ARMFGYKRHKDTMRVFMPATIAQTFQEVYLGNEAIKNQLDHGTHINDIRVILGDGVA

PTRANVLDKRKVGNLSGGVNYFAADPRIKNVEALDKKLLAYLDKHGEDSTIGMRAII

TILNAFTVDPNDLDLATFKAALLDFERNQPHLTARMVLRTNRKVNQGTGALLSPTDQ

ALSRAEVAHPLLILYRIEGVNDAAAQRGEPTWSSDPIWVPNIKLPGQRQFWCVDG

SEQ ID NO: 13; DNA; Orotate phosphoribosyltransferase pyrE;

CGL_RS13820, ncgl2676, cgl2773

ATGTCATCTAATTCCATTAACGCAGAAGCGCGCGCTGAGCTTGCTGAACTGATCAA

AGAGCTAGCTGTCGTCCACGGTGAAGTCACCTTGTCTTCGGGCAAGAAGGCTGATT

ACTACATCGATGTCCGTCGTGCCACCTTGCACGCGCGCGCATCTCGCCTGATCGGT

CAGCTGCTGCGCGAAGCCACCGCTGACTGGGACTATGACGCAGTTGGCGGCCTGA

CCTTGGGCGCTGACCCGGTTGCCACCGCCATCATGCACGCCGACGGCCGCGATATC

AACGCGTTTGTGGTGCGCAAGGAGGCCAAGAAGCACGGCATGCAGCGTCGCATTG

AGGGCCCTGACCTGACGGGCAAGAAGGTGCTCGTGGTGGAAGATACCACCACCAC

CGGAAATTCCCCTCTGACAGCTGTTGCCGCGTTGCGTGAAGCTGGCATTGAGGTTG

TGGGCGTTGCCACCGTGGTCGATCGCGCAACCGGTGCAGATGAGGTTATCGCAGC

GGAAGGCCTTCCTTACCGCAGCTTGCTGGGACTTTCTGATCTTGGACTCAACTAA

SEQ ID NO: 14; PRT; Orotate phosphoribosyltransferase pyrE;

CGL_RS13820, ncgl2676, cgl2773

MSSNSINAEARAELAELIKELAVVHGEVTLSSGKKADYYIDVRRATLHARASRLIGQL

LREATADWDYDAVGGLTLGADPVATAIMHADGRDINAFVVRKEAKKHGMQRRIEGP

DLTGKKVLVVEDTTTTGNSPLTAVAALREAGIEVVGVATVVDRATGADEVIAAEGLP

YRSLLGLSDLGLN

SEQ ID NO: 15; DNA; 5′-nucleotidase ushA; cgl0328-CGL_RS01710,

ncgl0322, cg0397

ATGAAGAGGCTTTCCCGTGCAGCCCTCGCAGTGGTCGCCACCACCGCAGTTAGCTT

CAGCGCACTCGCAGTTCCAGCTTTCGCAGACGAAGCAAGCAATGTTGAGCTCAAC

ATCCTCGGTGTCACCGACTTCCACGGACACATCGAGCAGAAGGCTGTTAAAGATG

ATAAGGGAGTAATCACCGGTTACTCAGAAATGGGTGCCAGTGGCGTTGCCTGCTA

CGTCGACGCTGAACGCGCGGACAACCCAAACACCCGCTTCATCACCGTTGGTGAC

AACATTGGTGGATCCCCATTCGTGTCCTCCATCCTGAAGGATGAGCCAACCTTGCA

AGCCCTCAGCGCCATCGGTGTTGACGCATCCGCACTGGGCAATCACGAATTCGAC

CAGGGCTACTCAGACCTGGTGAACCGCGTTTCCCTCGACGGCTCCGGCAGCGCAA

AGTTCCCATACCTCGGCGCAAACGTTGAAGGTGGCACCCCAGCACCTGCAAAGTC

TGAAATCATCGAGATGGACGGCGTCAAGATCGCTTACGTCGGCGCAGTAACCGAG

GAGACCGCAACCTTGGTCTCCCCAGCAGGCATCGAAGGCATCACCTTCACCGGCG

ACATCGACGCTATCAACGCAGAAGCAGATCGCGTCATTGAGGCAGGCGAAGCAGA

CGTAGTCATCGCATTGATCCACGCTGAAGCCGCTCCAACCGATCTATTCTCCAACA

ACGTTGACGTTGTATTCTCCGGACACACCCACTTCGACTACGTTGCTGAAGGCGAA

GCACGTGGCGACAAGCAGCCACTCGTTGTCATCCAGGGCCACGAATACGGCAAGG

TCATCTCCGACGTGGAGATCTCCTACGACCGCGAAGCAGGCAAGATCACCAACAT

TGAGGCGAAGAATGTCTCTGCTACTGACGTTGTGGAAAACTGTGAGACTCCAAAC

ACAGCAGTCGACGCAATCGTTGCAGCTGCTGTTGAGGCCGCTGAAGAAGCAGGTA

ATGAAGTTGTTGCAACCATTGACAACGGCTTCTACCGTGGGGCGGATGAAGAGGG

TACGACCGGCTCCAACCGTGGTGTTGAGTCTTCCCTGAGCAACCTCATCGCAGAAG

CTGGACTGTGGGCAGTCAACGACGCGACCATCCTGAACGCTGACATCGGCATCAT

GAACGCAGGCGGCGTGCGTGCGGACCTCGAAGCAGGCGAAGTTACCTTCGCAGAT

GCATACGCAACCCAGAACTTCTCCAACACCTACGGCGTACGTGAAGTGTCTGGTG

CGCAGTTCAAAGAAGCACTGGAACAGCAGTGGAAGGAAACCGGCGACCGCCCAC

GTCTGGCATTGGGACTGTCCAGCAACGTCCAGTACTCCTACGACGAGACCCGCGA

ATACGGCGACCGCATCACCCACATCACCTTCAACGGTGAGCCAATGGATATGAAG

GAGACCTACCGCGTCACAGGATCATCCTTCCTGCTCGCAGGTGGCGACTCCTTCAC

TGCATTCGCTGAAGGCGGCCCAATCGCTGAAACCGGCATGGTTGACATTGACCTGT

TCAACAACTACATCGCAGCTCACCCAGATGCACCAATTCGTGCAAATCAGAGCTC

AGTAGGCATCGCCCTTTCCGGCCCGGCAGTTGCAGAAGACGGAACTTTGGTCCCTG

GTGAAGAGCTGACCGTCGATCTTTCTTCCCTCTCCTACACCGGACCTGAAGCTAAG

CCAACCACCGTTGAGGTGACCGTTGGTACTGAGAAGAAGACTGCGGACGTCGATA

ACACCATCGTTCCTCAGTTTGACAGCACCGGCAAGGCAACTGTCACCCTGACTGTT

CCTGAGGGAGCTACCTCTGTCAAGATCGCAACTGACAATGGCACTACCTTTGAACT

GCCAGTAACCGTAAACGGTGAAGGCAACAATGATGACGATGATGATAAGGAGCA

GCAGTCCTCCGGATCCTCCGACGCCGGTTCCCTTGTAGCAGTTCTCGGTGTTCTTG

GAGCACTCGGTGGCCTGGTGGCGTTCTTCCTGAACTCTGCGCAGGGCGCACCATTC

TTGGCTCAGCTTCAGGCTATGTTTGCGCAGTTCATGTAA

SEQ ID NO: 16; PRT; 5′-nucleotidase ushA; cgl0328-CGL_RS01710,

ncgl0322, cg0397

MKRLSRAALAVVATTAVSFSALAVPAFADEASNVELNILGVTDFHGHIEQKAVKDDK

GVITGYSEMGASGVACYVDAERADNPNTRFITVGDNIGGSPFVSSILKDEPTLQALSAI

GVDASALGNHEFDQGYSDLVNRVSLDGSGSAKFPYLGANVEGGTPAPAKSEIIEMDG

VKIAYVGAVTEETATLVSPAGIEGITFTGDIDAINAEADRVIEAGEADVVIALIHAEAAP

TDLFSNNVDVVFSGHTHFDYVAEGEARGDKQPLVVIQGHEYGKVISDVEISYDREAG

KITNIEAKNVSATDVVENCETPNTAVDAIVAAAVEAAEEAGNEVVATIDNGFYRGAD

EEGTTGSNRGVESSLSNLIAEAGLWAVNDATILNADIGIMNAGGVRADLEAGEVTFAD

AYATQNFSNTYGVREVSGAQFKEALEQQWKETGDRPRLALGLSSNVQYSYDETREY

GDRITHITFNGEPMDMKETYRVTGSSFLLAGGDSFTAFAEGGPIAETGMVDIDLFNNYI

AAHPDAPIRANQSSVGIALSGPAVAEDGTLVPGEELTVDLSSLSYTGPEAKPTTVEVTV

GTEKKTADVDNTIVPQFDSTGKATVTLTVPEGATSVKIATDNGTTFELPVTVNGEGNN

DDDDDKEQQSSGSSDAGSLVAVLGVLGALGGLVAFFLNSAQGAPFLAQLQAMFAQF

M

SEQ ID NO: 17; DNA; Nicotinamide ribose transporter pnuC;

ncgl0063, CGL_RS00355, cgl0064

ATGAATCCTATAACCGAATTATTAGACGCAACACTATGGATCGGCGGAGTTCCGA

TTCTGTGGCGCGAAATCATCGGCAACGTTTTCGGATTATTTAGCGCGTGGGCAGGA

ATGCGACGCATCGTGTGGGCATGGCCCATCGGCATCATAGGCAACGCGCTGCTGT

TCACAGTATTTATGGGCGGCCTTTTCCACACTCCACAAAACCTCGATCTCTACGGC

CAAGCGGGTCGCCAGATCATGTTCATCATCGTCAGTGGTTATGGCTGGTACCAATG

GTCGGCCGCAAAACGTCGCGCACTCACCCCAGAAAATGCAGTAGCAGTGGTTCCT

CGCTGGGCAAGCACCAAAGAACGCGCCGGCATTGTGATTGCGGCGGTTGTGGGAA

CACTCAGCTTTGCCTGGATTTTCCAAGCACTCGGCTCCTGGGGGCCATGGGCCGAC

GCGTGGATTTTCGTCGGCTCAATCCTGGCTACCTACGGAATGGCTCGCGGATGGAC

AGAGTTCTGGCTGATCTGGATCGCCGTCGACATAGTTGGCGTTCCTCTACTTTTGA

CTGCTGGCTACTACCCATCCGCGGTGCTTTACCTGGTGTACGGTGCGTTTGTCAGC

TGGGGATTTGTCGTGTGGCTGCGGGTGCAAAAAGCAGACAAGGCTCGTGCGCTGG

AAGCTCAGGAGTCTGTGACAGTCTGA

SEQ ID NO: 18; PRT; Nicotinamide ribose transporter pnuC;

ncgl0063, CGL_RS00355, cgl0064

MNPITELLDATLWIGGVPILWREIIGNVFGLFSAWAGMRRIVWAWPIGIIGNALLFTVF

MGGLFHTPQNLDLYGQAGRQIMFIIVSGYGWYQWSAAKRRALTPENAVAVVPRWAS

TKERAGIVIAAVVGTLSFAWIFQALGSWGPWADAWIFVGSILATYGMARGWTEFWLI

WIAVDIVGVPLLLTAGYYPSAVLYLVYGAFVSWGFVVWLRVQKADKARALEAQESV

TV

SEQ ID NO: 19; DNA; Purine nucleosidase iunH3; cgl1364

(CGL_RS06810, ncgl1309, cgl543, iunH3)

ATGACCACCAAGATCATCCTCGACTGCGATCCAGGACACGACGACGCTGTAGCCA

TGCTGCTCGCAGCCGGCAGCCCAGAAATTGAACTGCTTGGAATCACCACGGTCGG

CGGCAACCAGACCTTGGACAAGGTCACCCACAATACGCAGGTCGTAGCCACCATC

GCTGATATCAATGCGCCCATCTACCGCGGTGTCACCCGACCATTGGTGCGCCCCGT

TGAGGTAGCCGAAGATATCCACGGCGATACCGGCATGGAAATCCACAAGTACGAA

CTGCCTGAACCAACCAAGCAGGTAGAAGACACCCACGCGGTGGATTTCATCATCG

ATACCATCATGAATAACGAGCCCGGCAGCGTAGCGCTGGTTCCCACCGGACCACT

GACCAACATCGCGCTGGCAGTCCGGAAAGAACCACGCATCGCCGAGCGAGTCAAG

GAAGTTGTCCTCATGGGGGGGGCTACCACGTAGGAAACTGGACCGCCGTAGCTG

AATTCAACATCAAGATCGACCCCGAAGCAGCCCACATCGTATTCAACGAAAAGTG

GCCACTGACTATGGTCGGCCTCGACCTTACCCACCAGGCGCTCGCAACACCTGAG

ATCGAAGCCAAGTTCAACGAGCTGGGCACCGACGTCGCCGACTTCGTCGTCGCGC

TTTTCGACGCTTTCCGCAAGAATTACCAGGACGCACAGGGTTTTGATAACCCACCA

GTACACGACCCTTGTGCTGTTGCATACCTTGTTGACCCAACCGTATTCACCACCCG

CAAAGCACCACTCGATGTGGAGCTGTACGGCGCACTCACCACAGGCATGACCGTT

GCTGATTTCCGCGCACCGGCTCCAGCAGATTGCACCACCCAAGTAGCTGTTGACCT

GGACTTTGATAAATTCTGGAACATGGTGATCGATGCAGTAAAGCGCATCGGATAG

SEQ ID NO: 20; PRT; Purine nucleosidase iunH3; cgl1364

(CGL_RS06810, ncgl1309, cg1543, iunH3)

MTTKIILDCDPGHDDAVAMLLAAGSPEIELLGITTVGGNQTLDKVTHNTQVVATIADI

NAPIYRGVTRPLVRPVEVAEDIHGDTGMEIHKYELPEPTKQVEDTHAVDFIIDTIMNNE

PGSVALVPTGPLTNIALAVRKEPRIAERVKEVVLMGGGYHVGNWTAVAEFNIKIDPEA

AHIVFNEKWPLTMVGLDLTHQALATPEIEAKFNELGTDVADFVVALFDAFRKNYQDA

QGFDNPPVHDPCAVAYLVDPTVFTTRKAPLDVELYGALTTGMTVADFRAPAPADCTT

QVAVDLDFDKFWNMVIDAVKRIG

SEQ ID NO: 21; DNA; Purine nucleosidase iunH2; cgl1977

(cg2168, iunH2, CYL77_RS09970)

ATGAGCAAAAAAGCCATCCTTGATATCGACACCGGCATCGATGATGCCCTCGCAC

TTGCCTACGCACTGGGCTCACCTGAACTAGAGCTCATTGGTGTCACCACCACCTAC

GGTAACGTGCTACTCGAAACCGGTGCAGTCAATGACCTGGCACTGCTTGATCTGTT

CGGTGCACCAGAAGTACCTGTGTACTTGGGTGAGCCACACGCACAGACCAAGGAT

GGCTTTGAAGTTCTTGAGATCTCCGCGTTCATTCACGGACAAAACGGCATCGGCGA

AGTCGAGCTGCCAGCAAGCGAGTCAAAGGCACTCCCCGGCGCAGTGGATTTCCTC

ATTGATTCCGTCAACACCCACGGCGATGACCTGGTGATCATCGCAACTGGTCCCAT

GACCAACCTGTCTGCGGCAATCGCAAAGGATCCAAGCTTTGCTTCCAAGGCTCAC

GTGGTCATCATGGGTGGCGCCTTGACTGTCCCAGGCAACGTCAGCACATGGGCAG

AAGCAAACATCAACCAGGACCCAGATGCAGCAAACGATCTGTTCCGTTCCGGTGC

AGATGTCACCATGATCGGTCTTGATGTCACCCTGCAGACCCTTCTTACCAAGAAGC

ACACTGCGCAGTGGCGCGAACTGGGCACTCCAGCTGCTATCGCACTGGCCGACAT

GACTGATTACTACATCAAGGCATATGAGACCACCGCACCACACCTGGGCGGTTGC

GGCCTGCACGACCCACTGGCAGTAGGCGTTGCAGTGGACCCAAGCCTGGTCACTT

TGCTCCCCATCAACCTCAAGGTAGACATTGAGGGCGAGACCCGTGGACGCACCAT

TGGCGATGAAGTCCGCCTCAACGATCCAGTGCGCACCTCCCGCGCAGCTGTCGCC

GTAGACGTGGATCGTTTCCTTTCTGAATTCATGACCCGCATCGGCCGAGTCGCAGC

ACAGCAGTAA

SEQ ID NO: 22; PRT; Purine nucleosidase iunH2; cgl1977

(cg2168, iunH2, CYL77_RS09970)

MSKKAILDIDTGIDDALALAYALGSPELELIGVTTTYGNVLLETGAVNDLALLDLFGAP

EVPVYLGEPHAQTKDGFEVLEISAFIHGQNGIGEVELPASESKALPGAVDFLIDSVNTH

GDDLVIIATGPMTNLSAAIAKDPSFASKAHVVIMGGALTVPGNVSTWAEANINQDPDA

ANDLFRSGADVTMIGLDVTLQTLLTKKHTAQWRELGTPAAIALADMTDYYIKAYETT

APHLGGCGLHDPLAVGVAVDPSLVTLLPINLKVDIEGETRGRTIGDEVRLNDPVRTSR

AAVAVDVDRFLSEFMTRIGRVAAQQ

SEQ ID No.: 23; DNA; Purine nucleosidase iunH1; cgl2835

(cg3137, iunH1, CYL77_RS14340)

ATGATTCCTGTTCTCATCGACTGCGACACCGGCATCGACGACGCC

CTCGCCCTGATCTACCTGGTTGCTTTGCATAAACGTGGTGAAATCCAACTTTTTGG

AGCAACGACCACCGCAGGAAATGTTGATGTGAAACAAACCGCCTCAATACCAGGT

GGGTGTTGGATCAGTGTGGATTAGCGGACATCCCGGTCCTCGCAGGACAACCTGA

ACCAAAGCACGTGCCGCTAGTGACTACTCCAGAAACACACGGCGACCATGGCCTT

GGTTATATAAACCCAGGTCACGTCGAAATTCCAGAAGGTGACTGGAAGCAGCTGT

GGAAAGAACACCTCAGTAACCCAGAAACTAAGCTGATTGTCACCGGGCCCGCCAC

CAACCTTGCGGAATTCGGGCCAGTGGAAAACGTCACGCTGATGGGTGGCACCTAC

CTTTATCCAGGCAACACCACTCCAACGGCAGAATGGAATACCTGGGTTGATCCAC

ACGGAGCTAAAGAAGCATTCGCGGCAGCCCAAAAGCCCATTACGGTGTGTTCCTT

GGGCGTGACCGAGCAGTTTACGCTGAACCCGGACATCCTTTCTACACTTATCAACA

CGCTTGGCAGCCAACCCATCGCAGAGCATTTACCTGAGATGCTGCGCTTTTACTTT

GAATTTCACGAAGTGCAGGGCGAAGGTTACCTTGCTCAAATTCATGACCTGCTGAC

CTGCATGATTGCCTTGGATAAAATCCCATTTTCAGGCCGTGAAGTAACCGTGGACG

TGGAGGCTGATTCGCCCTTGATGCGTGGCACCACTGTTGCAGATATTCGCGGACAT

TGGGGCAAGCCAGCTAACGCATTTCTTGTGGAAACCGCAGACATTGAGGCCGCCC

ACGCGGAACTTCTAAGAGCAGTGGAATGA

SEQ ID No.: 24; PRT; Purine nucleosidase iunH1; cgl2835

(cg3137, iunH1, CYL77_RS14340)

MIPVLIDCDTGIDDALALIYLVALHKRGEIQLFGATTTAGNVDVKQTAINTRWVLDQC

GLADIPVLAGQPEPKHVPLVTTPETHGDHGLGYINPGHVEIPEGDWKQLWKEHLSNPE

TKLIVTGPATNLAEFGPVENVTLMGGTYLYPGNTTPTAEWNTWVDPHGAKEAFAAA

QKPITVCSLGVTEQFTLNPDILSTLINTLGSQPIAEHLPEMLRFYFEFHEVQGEGYLAQI

HDLLTCMIALDKIPFSGREVTVDVEADSPLMRGTTVADIRGHWGKPANAFLVETADIE

AAHAELLRAVE

SEQ ID No. 25; DNA; glucose-6P isomerase pgi; cgl0851

(ncgl0817)

ATGGCGGACATTTCGACCACCCAGGTTTGGCAAGACCTGACCGATCATTACTCAA

ACTTCCAGGCAACCACTCTGCGTGAACTTTTCAAGGAAGAAAACCGCGCCGAGAA

GTACACCTTCTCCGCGGCTGGCCTCCACGTCGACCTGTCGAAGAATCTGCTTGACG

ACGCCACCCTCACCAAGCTCCTTGCACTGACCGAAGAATCTGGCCTTCGCGAACGC

ATTGACGCGATGTTTGCCGGTGAACACCTCAACAACACCGAAGACCGCGCTGTCC

TCCACACCGCGCTGCGCCTTCCTGCCGAAGCTGATCTGTCAGTAGATGGCCAAGAT

GTTGCTGCTGATGTCCACGAAGTTTTGGGACGCATGCGTGACTTCGCTACTGCGCT

GCGCTCAGGCAACTGGTTGGGACACACCGGCCACACGATCAAGAAGATCGTCAAC

ATTGGTATCGGTGGCTCTGACCTCGGACCAGCCATGGCTACGAAGGCTCTGCGTGC

ATACGCGACCGCTGGTATCTCAGCAGAATTCGTCTCCAACGTCGACCCAGCAGAC

CTCGTTTCTGTGTTGGAAGACCTCGATGCAGAATCCACATTGTTCGTGATCGCTTC

GAAAACTTTCACCACCCAGGAGACGCTGTCCAACGCTCGTGCAGCTCGTGCTTGGC

TGGTAGAGAAGCTCGGTGAAGAGGCTGTCGCGAAGCACTTCGTCGCAGTGTCCAC

CAATGCTGAAAAGGTCGCAGAGTTCGGTATCGACACGGACAACATGTTCGGCTTC

TGGGACTGGGTCGGAGGTCGTTACTCCGTGGACTCCGCAGTTGGTCTTTCCCTCAT

GGCAGTGATCGGCCCTCGCGACTTCATGCGTTTCCTCGGTGGATTCCACGCGATGG

ATGAACACTTCCGCACCACCAAGTTCGAAGAGAACGTTCCAATCTTGATGGCTCTG

CTCGGTGTCTGGTACTCCGATTTCTATGGTGCAGAAACCCACGCTGTCCTACCTTA

TTCCGAGGATCTCAGCCGTTTTGCTGCTTACCTCCAGCAGCTGACCATGGAATCAA

ATGGCAAGTCAGTCCACCGCGACGGCTCCCCTGTTTCCACTGGCACTGGCGAAATT

TACTGGGGTGAGCCTGGCACAAATGGCCAGCACGCTTTCTTCCAGCTGATCCACCA

GGGCACTCGCCTTGTTCCAGCTGATTTCATTGGTTTCGCTCGTCCAAAGCAGGATC

TTCCTGCCGGTGAGCGCACCATGCATGACCTTTTGATGAGCAACTTCTTCGCACAG

ACCAAGGTTTTGGCTTTCGGTAAGAACGCTGAAGAGATCGCTGCGGAAGGTGTCG

CACCTGAGCTGGTCAACCACAAGGTCATGCCAGGTAATCGCCCAACCACCACCAT

TTTGGCGGAGGAACTTACCCCTTCTATTCTCGGTGCGTTGATCGCTTTGTACGAAC

ACATCGTGATGGTTCAGGGCGTGATTTGGGACATCAACTCCTTCGACCAATGGGGT

GTTGAACTGGGCAAACAGCAGGCAAATGACCTCGCTCCGGCTGTCTCTGGTGAAG

AGGATGTTGACTCGGGAGATTCTTCCACTGATTCACTGATTAAGTGGTACCGCGCA

AATAGGTAG

SEQ ID No. 26; PRT; glucose-6P isomerase PGI; cgl0851

(ncgl0817)

MADISTTQVWQDLTDHYSNFQATTLRELFKEENRAEKYTFSAAGLHVDLSKNLLDDA

TLTKLLALTEESGLRERIDAMFAGEHLNNTEDRAVLHTALRLPAEADLSVDGQDVAA

DVHEVLGRMRDFATALRSGNWLGHTGHTIKKIVNIGIGGSDLGPAMATKALRAYATA

GISAEFVSNVDPADLVSVLEDLDAESTLFVIASKTFTTQETLSNARAARAWLVEKLGEE

AVAKHFVAVSTNAEKVAEFGIDTDNMFGFWDWVGGRYSVDSAVGLSLMAVIGPRDF

MRFLGGFHAMDEHFRTTKFEENVPILMALLGVWYSDFYGAETHAVLPYSEDLSRFAA

YLQQLTMESNGKSVHRDGSPVSTGTGEIYWGEPGINGQHAFFQLIHQGTRLVPADFIG

FARPKQDLPAGERTMHDLLMSNFFAQTKVLAFGKNABEIAAEGVAPELVNHKVMPG

NRPTTTILAEELTPSILGALIALYEHIVMVQGVIWDINSFDQWGVELGKQQANDLAPAV

SGEEDVDSGDSSTDSLIKWYRANR

SEQ ID No. 27; DNA; cgZWF codon-optimized mutant (A243T)

of the of the glucose-6-phosphate dehydrogenase from

Corynebacterium glutamicum (cg1778, Cgl1576, NCgl1514)

ATGAGTACCAACACCACCCCGTCAAGCTGGACAAATCCATTGCGCGACCCCCAGG

ATAAGCGCTTGCCCCGCATCGCAGGACCCTCCGGCATGGTCATTTTTGGGGTGACC

GGCGATCTGGCACGCAAGAAACTGCTACCAGCCATCTATGACTTGGCAAATCGCG

GCTTACTGCCACCTGGCTTCTCTCTCGTGGGCTATGGTCGCCGTGAATGGTCTAAG

GAGGACTTCGAAAAGTACGTTCGTGATGCAGCGTCCGCGGGAGCCCGAACGGAAT

TTCGTGAAAACGTCTGGGAACGCCTTGCAGAAGGCATGGAATTTGTCCGCGGAAA

TTTTGATGATGACGCCGCATTCGACAACTTGGCGGCGACGCTGAAGCGCATCGAT

AAGACGAGAGGCACTGCTGGTAACTGGGCGTACTATCTGTCCATCCCACCGGACT

CCTTTACGGCGGTGTGCCACCAGCTAGAGCGTTCCGGCATGGCTGAGTCCACCGA

AGAGGCATGGCGCCGAGTGATCATTGAAAAGCCATTCGGGCACAACCTGGAATCG

GCACACGAGCTCAACCAACTGGTCAACGCCGTTTTCCCGGAGTCATCAGTGTTTAG

AATCGATCACTACCTGGGTAAAGAAACCGTGCAGAATATCCTCGCGCTGCGATTC

GCAAATCAACTTTTTGAACCCCTTTGGAACAGCAACTATGTCGATCACGTCCAAAT

TACCATGACTGAAGATATTGGCTTGGGAGGACGCGCGGGTTATTATGATGGAATC

GGAGCAGCGCGCGACGTCATCCAGAATCACCTCATTCAGCTGTTGGCGCTGGTAG

CGATGGAGGAACCCATTAGCTTTGTGCCTGCTCAGCTGCAAGCAGAAAAGATCAA

AGTTCTGAGCGCTACCAAACCTTGTTACCCTCTGGATAAGACCTCAGCTCGCGGTC

AATATGCTGCTGGCTGGCAAGGATCTGAGCTGGTCAAGGGCCTTCGTGAAGAGGA

CGGTTTCAACCCCGAGAGCACCACGGAAACCTTCGCCGCATGTACCCTTGAAATC

ACAAGTCGCCGCTGGGCCGGCGTCCCATTCTACCTGCGTACTGGCAAGAGACTCG

GCCGACGAGTTACAGAGATCGCTGTTGTGTTTAAAGATGCTCCCCACCAGCCGTTT

GATGGAGACATGACCGTTTCCCTTGGCCAAAATGCGATCGTAATTCGCGTACAACC

AGACGAGGGTGTTCTTATCCGCTTTGGTTCCAAGGTGCCCGGTTCCGCTATGGAGG

TTCGTGACGTTAATATGGACTTCAGCTATAGCGAATCCTTCACCGAAGAGTCACCT

GAAGCATACGAACGCCTGATCCTGGATGCCCTCCTGGACGAGTCCAGCTTGTTTCC

AACCAACGAGGAAGTGGAACTGTCTTGGAAAATCCTGGACCCAATTCTGGAAGCT

TGGGATGCCGATGGCGAACCGGAGGACTACCCAGCTGGGACCTGGGGGCCAAAAT

CGGCGGATGAGATGTTATCCCGTAACGGCCACACATGGCGCCGACCTTGA

SEQ ID No. 28; DNA; cgZWF mutant (A243T) of the of the

glucose-6-phosphate dehydrogenase from Corynebacterium

glutamicum (cgl778, Cgl1576, NCgl1514)

MSTNTTPSSWTNPLRDPQDKRLPRIAGPSGMVIFGVTGDLARKKLLPAIYDLANRGLL

PPGFSLVGYGRREWSKEDFEKYVRDAASAGARTEFRENVWERLAEGMEFVRGNFDD

DAAFDNLAATLKRIDKTRGTAGNWAYYLSIPPDSFTAVCHQLERSGMAESTEEAWRR

VIIEKPFGHNLESAHELNQLVNAVFPESSVFRIDHYLGKETVQNILALRFANQLFEPLW

NSNYVDHVQITMAEDIGLGGRAGYYDGIGAARDVIQNHLIQLLALVAMEEPISFVPAQ

LQAEKIKVLSATKPCYPLDKTSARGQYAAGWQGSELVKGLREEDGENPESTTETFAA

CTLEITSRRWAGVPFYLRTGKRLGRRVTEIAVVFKDAPHQPFDGDMTVSLGQNAIVIR

VQPDEGVLIRF

GSKVPGSAMEVRDVNMDFSYSESFTEESPEAYERLILDALLDESSLFPTNEEVELSWKI

LDPILEAWDADGEPEDYPAGTWGPKSADEMLSRNGHTWRRP*

SEQ ID No. 29; DNA; glucose-6-phosphate dehydrogenase of

Leuconoston mesenteroides, codon optimized mutant (R46E/Q47E)

of the gene having accession number M64446.1; lmZWF

ATGGTTTCCGAAATAAAGACCCTCGTTACTTTCTTTGGCGGCACCGGTGACCTTGC

AAAACGCAAGCTCTACCCCTCTGTATTCAACCTGTACAAAAAAGGGTATCTGCAA

AAACACTTCGCCATTGTTGGTACCGCTGAAGAGGCGCTAAACGACGACGAGTTCA

AACAGCTTGTCCGTGATTCCATTAAAGACTTCACCGATGACCAAGCCCAGGCAGA

GGCCTTCATCGAACATTTTTCTTATCGAGCACACGATGTGACCGATGCCGCATCGT

ATGCAGTCCTGAAGGAAGCGATCGAGGAGGCGGCCGATAAGTTCGATATTGACGG

TAACCGCATATTTTACATGTCGGTGGCACCACGCTTCTTCGGTACCATCGCTAAAT

ATCTGAAGTCCGAGGGTCTGCTTGCTGATACTGGCTACAATCGGCTGATGATTGAA

AAGCCTTTTGGAACCTCTTATGACACAGCCGCAGAACTACAGAATGACTTGGAGA

ACGCTTTCGATGATAATCAGCTTTTCCGTATCGATCATTATCTGGGTAAAGAAATG

GTCCAGAATATCGCAGCTCTGCGCTTCGGAAACCCTATATTCGACGCTGCGTGGAA

CAAGGATTACATCAAGAACGTTCAAGTTACACTCTCCGAAGTGTTGGGGGTTGAA

GAGCGAGCCGGCTACTATGACACCGCCGGAGCTCTACTTGATATGATCCAGAACC

ACACGATGCAGATCGTTGGCTGGCTCGCCATGGAAAAACCAGAGTCCTTCACCGA

TAAAGACATCCGCGCGGCTAAGAACGCCGCTTTTAATGCCCTGAAAATCTACGAC

GAGGCTGAAGTGAACAAATATTTTGTGCGTGCCCAATATGGTGCTGGAGATTCTGC

CGATTTCAAACCTTACTTAGAGGAACTCGATGTCCCAGCAGATTCCAAAAACAAC

ACCTTCATTGCAGGCGAATTACAGTTTGATCTTCCACGTTGGGAAGGTGTGCCTTT

TTACGTGCGCAGCGGTAAACGACTCGCAGCCAAACAGACTCGCGTCGATATTGTTT

TCAAGGCTGGCACCTTTAATTTCGGGTCTGAACAGGAAGCTCAAGAGGCCGTTCTG

TCCATCATCATTGATCCGAAGGGAGCAATCGAACTGAAGCTCAATGCAAAATCTG

TGGAAGATGCTTTCAACACCCGCACTATCGACTTGGGCTGGACCGTGAGCGATGA

GGACAAGAAAAATACGCCAGAACCTTATGAAAGGATGATCCACGATACGATGAA

CGGTGACGGCAGCAACTTCGCAGATTGGAATGGCGTGAGCATTGCGTGGAAGTTC

GTAGATGCTATTTCTGCGGTATATACGGCCGATAAGGCCCCGCTTGAAACCTACAA

GTCGGGCTCCATGGGACCCGAAGCCAGCGACAAATTGCTCGCCGCAAACGGAGAT

GCATGGGTATTCAAGGGGTAG

SEQ ID No. 30; PRT; mutant (R46E/Q47E) of the glucose-6-

phosphate dehydrogenase of Leuconoston.mesenteroides; lmZWF

MVSEIKTLVTFFGGTGDLAKRKLYPSVFNLYKKGYLQKHFAIVGTAEEALNDDEFKQ

LVRDSIKDFTDDQAQAEAFIEHFSYRAHDVTDAASYAVLKEAIEEAADKFDIDGNRIFY

MSVAPRFFGTIAKYLKSEGLLADTGYNRLMIEKPFGTSYDTAAELQNDLENAFDDNQL

FRIDHYLGKEMVQNIAALRFGNPIFDAAWNKDYIKNVQVTLSEVLGVEERAGYYDTA

GALLDMIQNHTMQIVGWLAMEKPESFTDKDIRAAKNAAFNALKIYDEAEVNKYFVR

AQYGAGDSADFKPYLEELDVPADSKNNTFIAGELQFDLPRWEGVPFYVRSGKRLAAK

QTRVDIVFKAGTFNFGSEQEAQEAVLSIIIDPKGAIELKLNAKSVEDAFNTRTIDLGWT

VSDEDKKNTPEPYERMIHDTMNGDGSNFADWNGVSIAWKFVDAISAVYTADKAPLE

TYKSGSMGPEASDKLLAANGDAWVFKG

SEQ ID No. 31; DNA; Codon optimized variant of the glucose-

6-phosphate dehydrogenase from Zymomonas mobilis strain

ATCC 10988 (Zmob_0908)

ATGACTAATACTGTTTCTACCATGATCCTTTTCGGCAGCACCGGAGATCTCTCGCA

GCGCATGCTTCTTCCCTCGCTGTACGGGCTGGATGCAGACGGTCTACTCGCCGACG

ACCTCCGCATTGTGTGTACCTCTCGTTCCGAGTACGATACCGACGGATTTCGTGAT

TTTGCTGAGAAGGCACTGGACCGTTTCGTTGCCTCCGACAGACTTAATGATGATGC

AAAAGCGAAGTTCCTCAACAAGCTTTTCTACGCAACGGTTGACATCACCGATCCA

ACCCAATTTGGAAAGCTCGCAGACCTCTGCGGTCCAGTCGAAAAGGGCATTGCAA

TCTACCTTTCCACAGCACCATCCTTGTTCGAAGGCGCAATTGCTGGCTTGAAACAG

GCGGGCCTGGCCGGCCCGACCTCCCGCCTTGCATTGGAAAAGCCCTTGGGTCAAG

ATCTTGCTTCCTCTGATCACATCAACGACGCAGTGCTGAAGGTTTTTTCCGAAAAA

CAAGTATACCGTATCGACCACTATCTTGGGAAAGAAACCGTCCAGAATCTCCTAA

CACTCCGCTTTGGAAATGCATTGTTCGAGCCGTTGTGGAACTCAAAGGGGATTGAC

CACGTGCAGATCTCCGTCGCTGAGACAGTGGGACTCGAAGGACGCATCGGCTACT

TTGACGGCTCCGGCTCCCTGCGAGACATGGTGCAGTCTCACATCCTGCAATTGGTT

GCCCTTGTAGCTATGGAGCCCCCGGCTCACATGGAAGCAAACGCGGTCCGCGACG

AAAAGGTTAAGGTGTTCCGTGCACTTCGTCCCATTAACAACGACACTGTTTTCACA

CACACCGTGACTGGCCAATACGGCGCCGGCGTGTCGGGGGGAAAGGAAGTTGCAG

GCTACATCGATGAGCTTGGACAACCGAGTGATACTGAAACCTTTGTTGCAATTAAA

GCACACGTGGATAACTGGCGCTGGCAGGGAGTTCCCTTCTACATCCGCACTGGTA

AACGGCTCCCTGCCCGCCGTTCAGAGATCGTCGTTCAGTTCAAACCAGTTCCCCAC

TCCATTTTTTCAAGCTCAGGAGGAATCCTTCAGCCTAATAAATTGCGCATTGTCCT

GCAACCAGACGAAACCATCCAAATCTCAATGATGGTCAAGGAACCAGGTCTTGAC

AGAAATGGTGCACACATGCGTGAGGTCTGGCTGGATCTCTCTTTGACCGACGTGTT

CAAAGATCGAAAGCGCCGGATTGCTTACGAGCGCCTTATGCTCGATCTGATTGAG

GGTGACGCAACCCTCTTCGTGCGCCGCGACGAGGTCGAGGCACAGTGGGTTTGGA

TCGACGGTATCCGGGAAGGCTGGAAGGCTAATAGCATGAAGCCTAAAACCTATGT

CTCCGGCACCTGGGGACCCTCCACCGCTATTGCATTGGCAGAGCGCGATGGCGTC

ACCTGGTACGACTAA

SEQ ID No. 32; PRT; codon-optimized variant of the glu6-

phosphate dehydrogenase from Zymomonas mobilis strain

ATCC 10988 (NCBI-ProteinID: AEH62743.1)

MTNTVSTMILFGSTGDLSQRMLLPSLYGLDADGLLADDLRIVCTSRSEYDTDGFRDFA

EKALDRFVASDRLNDDAKAKFLNKLFYATVDITDPTQFGKLADLCGPVEKGIAIYLST

APSLFEGAIAGLKQAGLAGPTSRLALEKPLGQDLASSDHINDAVLKVFSEKQVYRIDH

YLGKETVQNLLTLRFGNALFEPLWNSKGIDHVQISVAETVGLEGRIGYFDGSGSLRDM

VQSHILQLVALVAMEPPAHMEANAVRDEKVKVFRALRPINNDTVFTHTVTGQYGAG

VSGGKEVAGYIDELGQPSDTETFVAIKAHVDNWRWQGVPFYIRTGKRLPARRSEIVVQ

FKPVPHSIFSSSGGILQPNKLRIVLQPDETIQISMMVKEPGLDRNGAHMREVWLDLSLT

DVFKDRKRRIAYERLMLDLIEGDATLFVRRDEVEAQWVWIDGIREGWKANSMKPKT

YVSGTWGPSTAIALAERDGVTWYD*

SEQ ID No. 33; DNA; soluble Pyridine Nucleotide Transhydrogenase

from Escherichia coli; udhA (NP_418397.2, EG11428)

ATGCCACATTCCTACGATTACGATGCCATAGTAATAGGTTCCGGCCCCGGCGGCGA

AGGCGCTGCAATGGGCCTGGTTAAGCAAGGTGCGCGCGTCGCAGTTATCGAGCGT

TATCAAAATGTTGGCGGCGGTTGCACCCACTGGGGCACCATCCCGTCGAAAGCTCT

CCGTCACGCCGTCAGCCGCATTATAGAATTCAATCAAAACCCACTTTACAGCGACC

ATTCCCGACTGCTCCGCTCTTCTTTTGCCGATATCCTTAACCATGCCGATAACGTGA

TTAATCAACAAACGCGCATGCGTCAGGGATTTTACGAACGTAATCACTGTGAAAT

ATTGCAGGGAAACGCTCGCTTTGTTGACGAGCATACGTTGGCGCTGGATTGCCTGG

ACGGCAGCGTTGAAACACTAACCGCTGAAAAATTTGTTATTGCCTGCGGCTCTCGT

CCATATCATCCAACAGATGTTGATTTCACCCATCCACGCATTTACGACAGCGACTC

AATTCTCAGCATGCACCACGAACCGCGCCATGTACTTATCTATGGTGCTGGAGTGA

TCGGCTGTGAATATGCGTCGATCTTCCGCGGTATGGATGTAAAAGTGGATCTGATC

AACACCCGCGATCGCCTGCTGGCATTTCTCGATCAAGAGATGTCAGATTCTCTCTC

CTATCACTTCTGGAACAGTGGCGTAGTGATTCGTCACAACGAAGAGTACGAGAAG

ATCGAAGGCTGTGACGATGGTGTGATCATGCATCTGAAGTCGGGTAAAAAACTGA

AAGCTGACTGCCTGCTCTATGCCAACGGTCGCACCGGTAATACCGATTCGCTGGCG

TTACAGAACATTGGGCTAGAAACTGACAGCCGCGGACAGCTGAAGGTCAACAGCA

TGTATCAGACCGCACAGCCACACGTTTACGCGGTGGGCGACGTGATTGGTTATCCG

AGCCTGGCGTCGGCGGCCTATGACCAGGGGCGCATTGCCGCGCAGGCGCTGGTAA

AAGGCGAAGCCACCGCACATCTGATTGAAGATATCCCTACCGGTATTTACACCATC

CCGGAAATCAGCTCTGTGGGCAAAACCGAACAGCAGCTGACCGCAATGAAAGTGC

CATATGAAGTGGGCCGCGCCCAGTTTAAACATCTGGCACGCGCACAAATCGTCGG

CATGAACGTGGGCACGCTGAAAATTTTGTTCCATCGGGAAACAAAAGAGATTCTG

GGTATTCACTGCTTTGGCGAGCGCGCTGCCGAAATTATTCATATCGGTCAGGCGAT

TATGGAACAGAAAGGTGGCGGCAACACTATTGAGTACTTCGTCAACACCACCTTT

AACTACCCGACGATGGCGGAAGCCTATCGGGTAGCTGCGTTAAACGGTTTAAACC

GCCTGTTTTAA

SEQ ID No. 34; PRT; soluble Pyridine Nucleotide Transhydrogenase

from Escherichia coli; udhA (AAC76944)

MPHSYDYDAIVIGSGPGGEGAAMGLVKQGARVAVIERYQNVGGGCTHWGTIPSKAL

RHAVSRIIEFNQNPLYSDHSRLLRSSFADILNHADNVINQQTRMRQGFYERNHCEILQG

NARFVDEHTLALDCLDGSVETLTAEKFVIACGSRPYHPTDVDFTHPRIYDSDSILSMHH

EPRHVLIYGAGVIGCEYASIFRGMDVKVDLINTRDRLLAFLDQEMSDSLSYHFWNSGV

VIRHNEEYEKIEGCDDGVIMHLKSGKKLKADCLLYANGRTGNTDSLALQNIGLETDSR

GQLKVNSMYQTAQPHVYAVGDVIGYPSLASAAYDQGRIAAQALVKGEATAHLIEDIP

TGIYTIPEISSVGKTEQQLTAMKVPYEVGRAQFKHLARAQIVGMNVGTLKILFHRETKE

ILGIHCFGERAAEIIHIGQAIMEQKGGGNTIEYFVNTTFNYPTMAEAYRVAALNGLNRL

F

SEQ ID No. 35; DNA; “A” subunit of Membrane bound Pyridine

Nucleotide Transhydrogenase (pnt) from Escherichia coli

MG1655; ECK1598 (variant g1342a, NP_416120.1)

ATGCCACATTCCTACGATTACGATGCCATAGTAATAGGTTCCGGCCCCGGCGGCGA

AGGCGCTGCAATGGGCCTGGTTAAGCAAGGTGCGCGCGTCGCAGTTATCGAGCGT

TATCAAAATGTTGGCGGCGGTTGCACCCACTGGGGCACCATCCCGTCGAAAGCTCT

CCGTCACGCCGTCAGCCGCATTATAGAATTCAATCAAAACCCACTTTACAGCGACC

ATTCCCGACTGCTCCGCTCTTCTTTTGCCGATATCCTTAACCATGCCGATAACGTGA

TTAATCAACAAACGCGCATGCGTCAGGGATTTTACGAACGTAATCACTGTGAAAT

ATTGCAGGGAAACGCTCGCTTTGTTGACGAGCATACGTTGGCGCTGGATTGCCTGG

ACGGCAGCGTTGAAACACTAACCGCTGAAAAATTTGTTATTGCCTGCGGCTCTCGT

CCATATCATCCAACAGATGTTGATTTCACCCATCCACGCATTTACGACAGCGACTC

AATTCTCAGCATGCACCACGAACCGCGCCATGTACTTATCTATGGTGCTGGAGTGA

TCGGCTGTGAATATGCGTCGATCTTCCGCGGTATGGATGTAAAAGTGGATCTGATC

AACACCCGCGATCGCCTGCTGGCATTTCTCGATCAAGAGATGTCAGATTCTCTCTC

CTATCACTTCTGGAACAGTGGCGTAGTGATTCGTCACAACGAAGAGTACGAGAAG

ATCGAAGGCTGTGACGATGGTGTGATCATGCATCTGAAGTCGGGTAAAAAACTGA

AAGCTGACTGCCTGCTCTATGCCAACGGTCGCACCGGTAATACCGATTCGCTGGCG

TTACAGAACATTGGGCTAGAAACTGACAGCCGCGGACAGCTGAAGGTCAACAGCA

TGTATCAGACCGCACAGCCACACGTTTACGCGGTGGGCGACGTGATTGGTTATCCG

AGCCTGGCGTCGGCGGCCTATGACCAGGGGCGCATTGCCGCGCAGGCGCTGGTAA

AAGGCGAAGCCACCGCACATCTGATTGAAGATATCCCTACCGGTATTTACACCATC

CCGGAAATCAGCTCTGTGGGCAAAACCGAACAGCAGCTGACCGCAATGAAAGTGC

CATATGAAGTGGGCCGCGCCCAGTTTAAACATCTGGCACGCGCACAAATCGTCGG

CATGAACGTGGGCACGCTGAAAATTTTGTTCCATCGGGAAACAAAAGAGATTCTG

GGTATTCACTGCTTTGGCGAGCGCGCTGCCGAAATTATTCATATCGGTCAGGCGAT

TATGGAACAGAAAGGTGGCGGCAACACTATTGAGTACTTCGTCAACACCACCTTT

AACTACCCGACGATGGCGGAAGCCTATCGGGTAGCTGCGTTAAACGGTTTAAACC

GCCTGTTTTAA

SEQ ID No. 36; PRT; “A” subunit of Membrane bound Pyridine

Nucleotide Transhydrogenase (pnt) from Escherichia coli;

P07001.2 (A434T variant)

MRIGIPRERLTNETRVAATPKTVEQLLKLGFTVAVESGAGQLASFDDKAFVQAGAEIV

EGNSVWQSEIILKVNAPLDDEIALLNPGTTLVSFIWPAQNPELMQKLAERNVTVMAM

DSVPRISRAQSLDALSSMANIAGYRAIVEAAHEFGRFFTGQITAAGKVPPAKVMVIGA

GVAGLAAIGAANSLGAIVRAFDTRPEVKEQVQSMGAEFLELDFKEEAGSGDGYAKV

MSDAFIKAEMELFAAQAKEVDIIVTTALIPGKPAPKLITREMVDSMKAGSVIVDLAAQ

NGGNCEYTVPGEIFTTENGVKVIGYTDLPGRLPTQSSQLYGTNLVNLLKLLCKEKDGN

ITVDFDDVVIRGVTVIRAGEITWPAPPIQVSAQPQAAQKAAPEVKTEEKCTCSPWRKY

ALMALAIILFGWMASVAPKEFLGHFTVFALTCVVGYYVVWNVSHALHTPLMSVTNAI

SGIIVVGALLQIGQGGWVSFLSFIAVLIASINIFGGFTVTQRMLKMFRKN

SEQ ID No. 37; DNA; “B” subunit of Membrane bound Pyridine

Nucleotide Transhydrogenase (pntB) from Escherichia coli

(MG1655; ECK1597; NP_416119.1)

ATGTCTGGAGGATTAGTTACAGCTGCATACATTGTTGCCGCGATCCTGTTTATCTTC

AGTCTGGCCGGTCTTTCGAAACATGAAACGTCTCGCCAGGGTAACAACTTCGGTAT

CGCCGGGATGGCGATTGCGTTAATCGCAACCATTTTTGGACCGGATACGGGTAAT

GTTGGCTGGATCTTGCTGGCGATGGTCATTGGTGGGGCAATTGGTATCCGTCTGGC

GAAGAAAGTTGAAATGACCGAAATGCCAGAACTGGTGGCGATCCTGCATAGCTTC

GTGGGTCTGGCGGCAGTGCTGGTTGGCTTTAACAGCTATCTGCATCATGACGCGGG

AATGGCACCGATTCTGGTCAATATTCACCTGACGGAAGTGTTCCTCGGTATCTTCA

TCGGGGCGGTAACGTTCACGGGTTCGGTGGTGGCGTTCGGCAAACTGTGTGGCAA

GATTTCGTCTAAACCATTGATGCTGCCAAACCGTCACAAAATGAACCTGGCGGCTC

TGGTCGTTTCCTTCCTGCTGCTGATTGTATTTGTTCGCACGGACAGCGTCGGCCTGC

AAGTGCTGGCATTGCTGATAATGACCGCAATTGCGCTGGTATTCGGCTGGCATTTA

GTCGCCTCCATCGGTGGTGCAGATATGCCAGTGGTGGTGTCGATGCTGAACTCGTA

CTCCGGCTGGGCGGCTGCGGCTGCGGGCTTTATGCTCAGCAACGACCTGCTGATTG

TGACCGGTGCGCTGGTCGGTTCTTCGGGGGCTATCCTTTCTTACATTATGTGTAAG

GCGATGAACCGTTCCTTTATCAGCGTTATTGCGGGTGGTTTCGGCACCGACGGCTC

TTCTACTGGCGATGATCAGGAAGTGGGTGAGCACCGCGAAATCACCGCAGAAGAG

ACAGCGGAACTGCTGAAAAACTCCCATTCAGTGATCATTACTCCGGGGTACGGCA

TGGCAGTCGCGCAGGCGCAATATCCTGTCGCTGAAATTACTGAGAAATTGCGCGC

TCGTGGTATTAATGTGCGTTTCGGTATCCACCCGGTCGCGGGGCGTTTGCCTGGAC

ATATGAACGTATTGCTGGCTGAAGCAAAAGTACCGTATGACATCGTGCTGGAAAT

GGACGAGATCAATGATGACTTTGCTGATACCGATACCGTACTGGTGATTGGTGCTA

ACGATACGGTTAACCCGGCGGCGCAGGATGATCCGAAGAGTCCGATTGCTGGTAT

GCCTGTGCTGGAAGTGTGGAAAGCGCAGAACGTGATTGTCTTTAAACGTTCGATG

AACACTGGCTATGCTGGTGTGCAAAACCCGCTGTTCTTCAAGGAAAACACCCACA

TGCTGTTTGGTGACGCCAAAGCCAGCGTGGATGCAATCCTGAAAGCTCTGTAA

SEQ ID No. 38; “B” subunit of Membrane bound Pyridine

Nucleotide Transhydrogenase (pntB) from Escherichia coli;

P0AB69.1

MSGGLVTAAYIVAAILFIFSLAGLSKHETSRQGNNFGIAGMAIALIATIFGPDTGNVGWI

LLAMVIGGAIGIRLAKKVEMTEMPELVAILHSFVGLAAVLVGFNSYLHHDAGMAPILV

NIHLTEVFLGIFIGAVTFTGSVVAFGKLCGKISSKPLMLPNRHKMNLAALVVSFLLLIVF

VRTDSVGLQVLALLIMTAIALVFGWHLVASIGGADMPVVVSMLNSYSGWAAAAAGF

MLSNDLLIVTGALVGSSGAILSYIMCKAMNRSFISVIAGGFGTDGSSTGDDQEVGEHRE

ITAEETAELLKNSHSVIITPGYGMAVAQAQYPVAEITEKLRARGINVRFGIHPVAGRLP

GHMNVLLAEAKVPYDIVLEMDEINDDFADTDTVLVIGANDTVNPAAQDDPKSPIAGM

PVLEVWKAQNVIVFKRSMNTGYAGVQNPLFFKENTHMLFGDAKASVDAILKAL

	Number	Date	Country
Parent	PCT/US2021/030601	May 2021	US
Child	18052595		US

PRODUCTION OF NMN AND ITS DERIVATIVES VIA MICROBIAL PROCESSES

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

International Classifications

Abstract

Description

Claims

RELATED APPLICATIONS

Provisional Applications (1)

Continuations (1)